FALSE 2025 Q3 December 31 0000313616 xbrli:shares iso4217:USD iso4217:USD xbrli:shares dhr:business xbrli:pure dhr:segment dhr:reportingUnit iso4217:EUR iso4217:JPY iso4217:CHF 0000313616 2025-01-01 2025-09-26 0000313616 us-gaap:CommonStockMember 2025-01-01 2025-09-26 0000313616 dhr:A0.2SeniorNotesDue2026Member 2025-01-01 2025-09-26 0000313616 dhr:A2.1SeniorNotesDue2026Member 2025-01-01 2025-09-26 0000313616 dhr:A1.2SeniorNotesDue2027Member 2025-01-01 2025-09-26 0000313616 dhr:A0.45SeniorNotesDue2028Member 2025-01-01 2025-09-26 0000313616 dhr:A2.5SeniorNotesDue2030Member 2025-01-01 2025-09-26 0000313616 dhr:A0.75SeniorNotesDue2031Member 2025-01-01 2025-09-26 0000313616 dhr:A1.35SeniorNotesDue2039Member 2025-01-01 2025-09-26 0000313616 dhr:A1.8SeniorNotesDue2049Member 2025-01-01 2025-09-26 0000313616 2025-10-16 0000313616 2025-09-26 0000313616 2024-12-31 0000313616 2025-06-28 2025-09-26 0000313616 2024-06-29 2024-09-27 0000313616 2024-01-01 2024-09-27 0000313616 us-gaap:CommonStockMember 2025-09-26 0000313616 us-gaap:CommonStockMember 2025-06-27 0000313616 us-gaap:CommonStockMember 2024-09-27 0000313616 us-gaap:CommonStockMember 2024-06-28 0000313616 us-gaap:CommonStockMember 2024-12-31 0000313616 us-gaap:CommonStockMember 2023-12-31 0000313616 us-gaap:AdditionalPaidInCapitalMember 2025-06-27 0000313616 us-gaap:AdditionalPaidInCapitalMember 2024-06-28 0000313616 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000313616 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000313616 us-gaap:AdditionalPaidInCapitalMember 2025-06-28 2025-09-26 0000313616 us-gaap:AdditionalPaidInCapitalMember 2024-06-29 2024-09-27 0000313616 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-09-26 0000313616 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-27 0000313616 us-gaap:AdditionalPaidInCapitalMember 2025-09-26 0000313616 us-gaap:AdditionalPaidInCapitalMember 2024-09-27 0000313616 us-gaap:TreasuryStockCommonMember 2025-06-27 0000313616 us-gaap:TreasuryStockCommonMember 2024-06-28 0000313616 us-gaap:TreasuryStockCommonMember 2024-12-31 0000313616 us-gaap:TreasuryStockCommonMember 2023-12-31 0000313616 us-gaap:TreasuryStockCommonMember 2025-06-28 2025-09-26 0000313616 us-gaap:TreasuryStockCommonMember 2024-06-29 2024-09-27 0000313616 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-09-26 0000313616 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-09-27 0000313616 us-gaap:TreasuryStockCommonMember 2025-09-26 0000313616 us-gaap:TreasuryStockCommonMember 2024-09-27 0000313616 us-gaap:RetainedEarningsMember 2025-06-27 0000313616 us-gaap:RetainedEarningsMember 2024-06-28 0000313616 us-gaap:RetainedEarningsMember 2024-12-31 0000313616 us-gaap:RetainedEarningsMember 2023-12-31 0000313616 us-gaap:RetainedEarningsMember 2025-06-28 2025-09-26 0000313616 us-gaap:RetainedEarningsMember 2024-06-29 2024-09-27 0000313616 us-gaap:RetainedEarningsMember 2025-01-01 2025-09-26 0000313616 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-27 0000313616 us-gaap:RetainedEarningsMember 2025-09-26 0000313616 us-gaap:RetainedEarningsMember 2024-09-27 0000313616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-27 0000313616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-28 0000313616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000313616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000313616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-28 2025-09-26 0000313616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-29 2024-09-27 0000313616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-09-26 0000313616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-27 0000313616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-26 0000313616 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-27 0000313616 us-gaap:NoncontrollingInterestMember 2025-06-27 0000313616 us-gaap:NoncontrollingInterestMember 2024-06-28 0000313616 us-gaap:NoncontrollingInterestMember 2024-12-31 0000313616 us-gaap:NoncontrollingInterestMember 2023-12-31 0000313616 us-gaap:NoncontrollingInterestMember 2025-06-28 2025-09-26 0000313616 us-gaap:NoncontrollingInterestMember 2024-06-29 2024-09-27 0000313616 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-09-26 0000313616 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-09-27 0000313616 us-gaap:NoncontrollingInterestMember 2025-09-26 0000313616 us-gaap:NoncontrollingInterestMember 2024-09-27 0000313616 2024-09-27 0000313616 2023-12-31 0000313616 country:US us-gaap:PensionPlansDefinedBenefitMember dhr:DefinedBenefitPlanInsuranceAnnuityContractMember 2025-09-26 0000313616 us-gaap:FairValueAdjustmentToInventoryMember 2024-01-01 2024-09-27 0000313616 us-gaap:CommonStockMember 2025-06-28 2025-09-26 0000313616 us-gaap:CommonStockMember 2024-06-29 2024-09-27 0000313616 us-gaap:CommonStockMember 2025-01-01 2025-09-26 0000313616 us-gaap:CommonStockMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:BiotechnologySegmentMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:LifeSciencesMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:DiagnosticsMember 2025-06-28 2025-09-26 0000313616 srt:NorthAmericaMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:BiotechnologySegmentMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:LifeSciencesMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:DiagnosticsMember 2025-06-28 2025-09-26 0000313616 dhr:WesternEuropeMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:BiotechnologySegmentMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:LifeSciencesMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:DiagnosticsMember 2025-06-28 2025-09-26 0000313616 dhr:OtherDevelopedMarketsMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:BiotechnologySegmentMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:LifeSciencesMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:DiagnosticsMember 2025-06-28 2025-09-26 0000313616 dhr:HighGrowthMarketsMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:BiotechnologySegmentMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:LifeSciencesMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:DiagnosticsMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:BiotechnologySegmentMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:LifeSciencesMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:DiagnosticsMember 2025-06-28 2025-09-26 0000313616 dhr:RevenuefromContractwithCustomerMeasurementRecurringMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:BiotechnologySegmentMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:LifeSciencesMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:DiagnosticsMember 2025-06-28 2025-09-26 0000313616 dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember 2025-06-28 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:BiotechnologySegmentMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:LifeSciencesMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:DiagnosticsMember 2024-06-29 2024-09-27 0000313616 srt:NorthAmericaMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:BiotechnologySegmentMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:LifeSciencesMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:DiagnosticsMember 2024-06-29 2024-09-27 0000313616 dhr:WesternEuropeMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:BiotechnologySegmentMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:LifeSciencesMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:DiagnosticsMember 2024-06-29 2024-09-27 0000313616 dhr:OtherDevelopedMarketsMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:BiotechnologySegmentMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:LifeSciencesMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:DiagnosticsMember 2024-06-29 2024-09-27 0000313616 dhr:HighGrowthMarketsMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:BiotechnologySegmentMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:LifeSciencesMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:DiagnosticsMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:BiotechnologySegmentMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:LifeSciencesMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:DiagnosticsMember 2024-06-29 2024-09-27 0000313616 dhr:RevenuefromContractwithCustomerMeasurementRecurringMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:BiotechnologySegmentMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:LifeSciencesMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:DiagnosticsMember 2024-06-29 2024-09-27 0000313616 dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember 2024-06-29 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:BiotechnologySegmentMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:LifeSciencesMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:DiagnosticsMember 2025-01-01 2025-09-26 0000313616 srt:NorthAmericaMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:BiotechnologySegmentMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:LifeSciencesMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:DiagnosticsMember 2025-01-01 2025-09-26 0000313616 dhr:WesternEuropeMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:BiotechnologySegmentMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:LifeSciencesMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:DiagnosticsMember 2025-01-01 2025-09-26 0000313616 dhr:OtherDevelopedMarketsMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:BiotechnologySegmentMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:LifeSciencesMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:DiagnosticsMember 2025-01-01 2025-09-26 0000313616 dhr:HighGrowthMarketsMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:BiotechnologySegmentMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:LifeSciencesMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:DiagnosticsMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:BiotechnologySegmentMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:LifeSciencesMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:DiagnosticsMember 2025-01-01 2025-09-26 0000313616 dhr:RevenuefromContractwithCustomerMeasurementRecurringMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:BiotechnologySegmentMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:LifeSciencesMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:DiagnosticsMember 2025-01-01 2025-09-26 0000313616 dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember 2025-01-01 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:BiotechnologySegmentMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:LifeSciencesMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember srt:NorthAmericaMember dhr:DiagnosticsMember 2024-01-01 2024-09-27 0000313616 srt:NorthAmericaMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:BiotechnologySegmentMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:LifeSciencesMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:WesternEuropeMember dhr:DiagnosticsMember 2024-01-01 2024-09-27 0000313616 dhr:WesternEuropeMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:BiotechnologySegmentMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:LifeSciencesMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:OtherDevelopedMarketsMember dhr:DiagnosticsMember 2024-01-01 2024-09-27 0000313616 dhr:OtherDevelopedMarketsMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:BiotechnologySegmentMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:LifeSciencesMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:HighGrowthMarketsMember dhr:DiagnosticsMember 2024-01-01 2024-09-27 0000313616 dhr:HighGrowthMarketsMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:BiotechnologySegmentMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:LifeSciencesMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:DiagnosticsMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:BiotechnologySegmentMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:LifeSciencesMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementRecurringMember dhr:DiagnosticsMember 2024-01-01 2024-09-27 0000313616 dhr:RevenuefromContractwithCustomerMeasurementRecurringMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:BiotechnologySegmentMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:LifeSciencesMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember dhr:DiagnosticsMember 2024-01-01 2024-09-27 0000313616 dhr:RevenuefromContractwithCustomerMeasurementNonrecurringMember 2024-01-01 2024-09-27 0000313616 2025-09-27 2025-09-26 0000313616 2026-09-27 2025-09-26 0000313616 us-gaap:CorporateNonSegmentMember 2025-06-28 2025-09-26 0000313616 us-gaap:CorporateNonSegmentMember 2024-06-29 2024-09-27 0000313616 us-gaap:CorporateNonSegmentMember 2025-01-01 2025-09-26 0000313616 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-09-27 0000313616 us-gaap:OperatingSegmentsMember dhr:BiotechnologySegmentMember 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:BiotechnologySegmentMember 2024-12-31 0000313616 us-gaap:OperatingSegmentsMember dhr:LifeSciencesMember 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:LifeSciencesMember 2024-12-31 0000313616 us-gaap:OperatingSegmentsMember dhr:DiagnosticsMember 2025-09-26 0000313616 us-gaap:OperatingSegmentsMember dhr:DiagnosticsMember 2024-12-31 0000313616 us-gaap:CorporateNonSegmentMember 2025-09-26 0000313616 us-gaap:CorporateNonSegmentMember 2024-12-31 0000313616 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2022-10-01 2022-12-31 0000313616 2024-01-01 2024-12-31 0000313616 us-gaap:TradeNamesMember dhr:LifeSciencesMember 2024-01-01 2024-09-27 0000313616 us-gaap:TradeNamesMember dhr:LifeSciencesMember 2024-06-29 2024-09-27 0000313616 us-gaap:TradeNamesMember dhr:LifeSciencesMember 2025-01-01 2025-09-26 0000313616 us-gaap:TradeNamesMember dhr:LifeSciencesMember 2025-06-27 0000313616 dhr:LifeSciencesMember 2025-03-29 2025-06-27 0000313616 dhr:LifeSciencesMember 2024-06-29 2024-09-27 0000313616 us-gaap:TechnologyBasedIntangibleAssetsMember dhr:BiotechnologyAndDiagnosticsSegmentMember 2025-06-28 2025-09-26 0000313616 us-gaap:TechnologyBasedIntangibleAssetsMember dhr:BiotechnologyAndDiagnosticsSegmentMember 2025-01-01 2025-09-26 0000313616 dhr:BiotechnologySegmentMember us-gaap:BuildingMember 2025-01-01 2025-09-26 0000313616 dhr:ReportingUnitChangeInBusinessMember 2025-06-28 2025-09-26 0000313616 dhr:ReportingUnitsTotalMember 2025-06-28 2025-09-26 0000313616 srt:MinimumMember 2025-06-28 0000313616 srt:MaximumMember 2025-06-28 0000313616 2025-06-28 2025-06-28 0000313616 us-gaap:FairValueInputsLevel1Member 2025-09-26 0000313616 us-gaap:FairValueInputsLevel1Member 2024-12-31 0000313616 us-gaap:FairValueInputsLevel2Member 2025-09-26 0000313616 us-gaap:FairValueInputsLevel2Member 2024-12-31 0000313616 us-gaap:FairValueInputsLevel3Member 2025-09-26 0000313616 us-gaap:FairValueInputsLevel3Member 2024-12-31 0000313616 us-gaap:PartnershipMember 2024-12-31 0000313616 us-gaap:PartnershipMember 2025-09-26 0000313616 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2025-09-26 0000313616 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2025-09-26 0000313616 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-12-31 0000313616 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-12-31 0000313616 dhr:EuroDenominatedCommercialPaperMember us-gaap:CommercialPaperMember 2025-09-26 0000313616 dhr:EuroDenominatedCommercialPaperMember us-gaap:CommercialPaperMember 2024-12-31 0000313616 dhr:A3.35SeniorNotesDue2025Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A3.35SeniorNotesDue2025Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A0.2SeniorNotesDue2026Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A0.2SeniorNotesDue2026Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A2.1SeniorNotesDue2026Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A2.1SeniorNotesDue2026Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A0.3SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A0.3SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A1.2SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A1.2SeniorNotesDue2027Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A0.45SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A0.45SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A1.125BondsDue2028Member us-gaap:BondsMember 2024-12-31 0000313616 dhr:A1.125BondsDue2028Member us-gaap:BondsMember 2025-09-26 0000313616 dhr:A2.6SeniorUnsecuredNotesDue2029Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A2.6SeniorUnsecuredNotesDue2029Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A2.5SeniorNotesDue2030Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A2.5SeniorNotesDue2030Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A0.75SeniorNotesDue2031Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A0.75SeniorNotesDue2031Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A0.65SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A0.65SeniorNotesDue2032Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A1.35SeniorNotesDue2039Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A1.35SeniorNotesDue2039Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A3.25SeniorUnsecuredNotesDue2039Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A3.25SeniorUnsecuredNotesDue2039Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A4.375SeniorNotesDue2045Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A4.375SeniorNotesDue2045Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A1.8SeniorNotesDue2049Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A1.8SeniorNotesDue2049Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A3.4SeniorUnsecuredNotesDue2049Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A3.4SeniorUnsecuredNotesDue2049Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A26SeniorUnsecuredNotesDue2050Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:A26SeniorUnsecuredNotesDue2050Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A28SeniorUnsecuredNotesDue2051Member us-gaap:SeniorNotesMember 2025-09-26 0000313616 dhr:A28SeniorUnsecuredNotesDue2051Member us-gaap:SeniorNotesMember 2024-12-31 0000313616 dhr:OtherMember 2025-09-26 0000313616 dhr:OtherMember 2024-12-31 0000313616 us-gaap:RevolvingCreditFacilityMember dhr:ThirdAmendedAndRestatedMultiyearCreditFacilityMember us-gaap:LineOfCreditMember 2025-09-26 0000313616 dhr:EuroDenominatedCommercialPaperAnd2026BiopharmaEuroNotesMember 2025-09-26 0000313616 dhr:EuroDenominatedCommercialPaperMember us-gaap:CommercialPaperMember 2025-01-01 2025-09-26 0000313616 dhr:USDollarDenominatedCommercialPaperMember us-gaap:CommercialPaperMember 2025-09-26 0000313616 dhr:A3.35SeniorNotesDue2025Member us-gaap:SeniorNotesMember 2025-09-15 0000313616 dhr:A2027CHFBondsMember us-gaap:SubsequentEventMember 2025-10-10 0000313616 dhr:A2029CHFBondsMember us-gaap:SubsequentEventMember 2025-10-10 0000313616 dhr:A2033CHFBondsMember us-gaap:SubsequentEventMember 2025-10-10 0000313616 dhr:A2037CHFBondsMember us-gaap:SubsequentEventMember 2025-10-10 0000313616 dhr:A2045CHFBondsMember us-gaap:SubsequentEventMember 2025-10-10 0000313616 dhr:CHFBondsMember us-gaap:SubsequentEventMember 2025-10-10 0000313616 us-gaap:SubsequentEventMember 2025-10-10 2025-10-10 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2025-09-26 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2025-06-28 2025-09-26 0000313616 dhr:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember 2025-06-28 2025-09-26 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2025-09-26 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2025-06-28 2025-09-26 0000313616 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2025-09-26 0000313616 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2025-06-28 2025-09-26 0000313616 dhr:CashFlowAndNetInvestmentHedgesMember 2025-09-26 0000313616 dhr:CashFlowAndNetInvestmentHedgesMember 2025-06-28 2025-09-26 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2024-09-27 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2024-06-29 2024-09-27 0000313616 dhr:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember 2024-06-29 2024-09-27 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2024-09-27 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2024-06-29 2024-09-27 0000313616 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2024-09-27 0000313616 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2024-06-29 2024-09-27 0000313616 dhr:CashFlowAndNetInvestmentHedgesMember 2024-09-27 0000313616 dhr:CashFlowAndNetInvestmentHedgesMember 2024-06-29 2024-09-27 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2025-01-01 2025-09-26 0000313616 dhr:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember 2025-01-01 2025-09-26 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2025-01-01 2025-09-26 0000313616 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2025-01-01 2025-09-26 0000313616 dhr:CashFlowAndNetInvestmentHedgesMember 2025-01-01 2025-09-26 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember 2024-01-01 2024-09-27 0000313616 dhr:ForeignCurrencyDenominatedDebtMember us-gaap:NetInvestmentHedgingMember 2024-01-01 2024-09-27 0000313616 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-09-27 0000313616 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-09-27 0000313616 dhr:CashFlowAndNetInvestmentHedgesMember 2024-01-01 2024-09-27 0000313616 us-gaap:NetInvestmentHedgingMember 2025-09-26 0000313616 us-gaap:NetInvestmentHedgingMember 2024-12-31 0000313616 us-gaap:NetInvestmentHedgingMember us-gaap:LongTermDebtMember 2025-09-26 2025-09-26 0000313616 us-gaap:NetInvestmentHedgingMember us-gaap:LongTermDebtMember 2024-12-31 2024-12-31 0000313616 dhr:A2013RepurchaseProgramMember us-gaap:CommonStockMember 2013-07-16 0000313616 dhr:A2013RepurchaseProgramMember us-gaap:CommonStockMember 2025-09-26 0000313616 dhr:A2024RepurchaseProgramMember us-gaap:CommonStockMember 2024-07-22 0000313616 dhr:A2024RepurchaseProgramMember us-gaap:CommonStockMember 2025-09-26 0000313616 dhr:A2025RepurchaseProgramMember us-gaap:CommonStockMember 2025-09-09 0000313616 dhr:A2025RepurchaseProgramMember us-gaap:CommonStockMember 2025-09-26 0000313616 dhr:A2013RepurchaseProgramMember us-gaap:CommonStockMember 2024-06-29 2024-09-27 0000313616 dhr:A2013RepurchaseProgramMember us-gaap:CommonStockMember 2024-01-01 2024-09-27 0000313616 us-gaap:RelatedPartyMember dhr:A2013RepurchaseProgramMember us-gaap:CommonStockMember 2024-06-29 2024-09-27 0000313616 us-gaap:RelatedPartyMember dhr:A2013RepurchaseProgramMember us-gaap:CommonStockMember 2024-01-01 2024-09-27 0000313616 dhr:A2013And2024RepurchaseProgramMember 2025-01-01 2025-09-26 0000313616 dhr:A2024RepurchaseProgramMember us-gaap:CommonStockMember 2025-06-28 2025-09-26 0000313616 dhr:A2024RepurchaseProgramMember us-gaap:CommonStockMember 2025-01-01 2025-09-26 0000313616 us-gaap:RestrictedStockUnitsRSUMember 2025-06-28 2025-09-26 0000313616 us-gaap:RestrictedStockUnitsRSUMember 2024-06-29 2024-09-27 0000313616 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-09-26 0000313616 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-27 0000313616 us-gaap:EmployeeStockOptionMember 2025-06-28 2025-09-26 0000313616 us-gaap:EmployeeStockOptionMember 2024-06-29 2024-09-27 0000313616 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-26 0000313616 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-27 0000313616 us-gaap:RestrictedStockUnitsRSUMember 2025-09-26 0000313616 us-gaap:EmployeeStockOptionMember 2025-09-26 0000313616 us-gaap:AccumulatedTranslationAdjustmentMember 2025-06-27 0000313616 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-06-27 0000313616 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-06-27 0000313616 us-gaap:AccumulatedTranslationAdjustmentMember 2025-06-28 2025-09-26 0000313616 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-06-28 2025-09-26 0000313616 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-06-28 2025-09-26 0000313616 us-gaap:AccumulatedTranslationAdjustmentMember 2025-09-26 0000313616 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-09-26 0000313616 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-09-26 0000313616 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-28 0000313616 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-06-28 0000313616 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-06-28 0000313616 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-29 2024-09-27 0000313616 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-06-29 2024-09-27 0000313616 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-06-29 2024-09-27 0000313616 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-27 0000313616 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-09-27 0000313616 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-09-27 0000313616 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0000313616 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-31 0000313616 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-31 0000313616 us-gaap:AccumulatedTranslationAdjustmentMember 2025-01-01 2025-09-26 0000313616 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-01-01 2025-09-26 0000313616 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-09-26 0000313616 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000313616 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000313616 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000313616 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-09-27 0000313616 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-01-01 2024-09-27 0000313616 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-09-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________________________________
FORM 10-Q
________________________________________________________
(Mark One)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 26, 2025
OR

☐ | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to
Commission File Number: 001-08089
DANAHER CORPORATION
(Exact name of registrant as specified in its charter)

Delaware |  | 59-1995548
(State of Incorporation) |  | (I.R.S. Employer Identification Number)
2200 Pennsylvania Avenue, N.W., Suite 800W |  | 20037-1701
Washington, | DC |
(Address of Principal Executive Offices) |  | (Zip Code)

Registrant’s telephone number, including area code: 202-828-0850

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, $0.01 par value | DHR | New York Stock Exchange
0.200% Senior Notes due 2026 | DHR/26 | New York Stock Exchange
2.100% Senior Notes due 2026 | DHR 26 | New York Stock Exchange
1.200% Senior Notes due 2027 | DHR/27 | New York Stock Exchange
0.450% Senior Notes due 2028 | DHR/28 | New York Stock Exchange
2.500% Senior Notes due 2030 | DHR 30 | New York Stock Exchange
0.750% Senior Notes due 2031 | DHR/31 | New York Stock Exchange
1.350% Senior Notes due 2039 | DHR/39 | New York Stock Exchange
1.800% Senior Notes due 2049 | DHR/49 | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer |  | ☒ |  | Accelerated Filer |  | ☐
Non-accelerated Filer |  | ☐ |  | Smaller Reporting Company |  | ☐
Emerging Growth Company |  | ☐ |  |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒
The number of shares of common stock outstanding at October 16, 2025 was 706,349,563.

DANAHER CORPORATION
INDEX
FORM 10-Q

|  | Page
PART I - | FINANCIAL INFORMATION |
Item 1. | Financial Statements |
| Consolidated Condensed Balance Sheets | 1
| Consolidated Condensed Statements of Earnings | 2
| Consolidated Condensed Statements of Comprehensive Income | 3
| Consolidated Condensed Statements of Stockholders’ Equity | 4
| Consolidated Condensed Statements of Cash Flows | 5
| Notes to Consolidated Condensed Financial Statements | 6
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 25
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 41
Item 4. | Controls and Procedures | 41
PART II - | OTHER INFORMATION |
Item 1. | Legal Proceedings | 42
Item 1A. | Risk Factors | 42
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 43
Item 5. | Other Information | 43
Item 6. | Exhibits | 44
| Signatures | 45

Table of Contents
DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
($ in millions, except per share amount)
(unaudited)

| September 26, 2025 |  | December 31, 2024
ASSETS |  |  |
Current assets: |  |  |
Cash and equivalents | $ | 1,528 |  |  | $ | 2,078 |
Trade accounts receivable, less allowance for doubtful accounts of $119 and $113, respectively | 3,755 |  |  | 3,537 |
Inventories: |  |  |
Finished goods | 1,373 |  |  | 1,145 |
Work in process | 526 |  |  | 465 |
Raw materials | 775 |  |  | 720 |
Total inventories | 2,674 |  |  | 2,330 |
Prepaid expenses and other current assets | 1,649 |  |  | 1,552 |
Total current assets | 9,606 |  |  | 9,497 |
Property, plant and equipment, net of accumulated depreciation of $4,666 and $4,101, respectively | 5,376 |  |  | 4,990 |
Other long-term assets | 3,870 |  |  | 3,990 |
Goodwill | 42,948 |  |  | 40,497 |
Other intangible assets, net | 18,097 |  |  | 18,568 |
Total assets | $ | 79,897 |  |  | $ | 77,542 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |
Current liabilities: |  |  |
Notes payable and current portion of long-term debt | $ | 23 |  |  | $ | 505 |
Trade accounts payable | 1,698 |  |  | 1,753 |
Accrued expenses and other liabilities | 4,603 |  |  | 4,540 |
Total current liabilities | 6,324 |  |  | 6,798 |
Other long-term liabilities | 5,660 |  |  | 5,694 |
Long-term debt | 16,833 |  |  | 15,500 |
Stockholders’ equity: |  |  |
Common stock - $0.01 par value, 2.0 billion shares authorized; 886.3 million issued and 706.3 million outstanding as of September 26, 2025; 884.3 million issued and 719.1 million outstanding as of December 31, 2024 | 9 |  |  | 9 |
Additional paid-in capital | 17,076 |  |  | 16,727 |
Treasury stock | (11,344) |  |  | (8,163) |
Retained earnings | 45,920 |  |  | 44,188 |
Accumulated other comprehensive income (loss) | (590) |  |  | (3,218) |
Total Danaher stockholders’ equity | 51,071 |  |  | 49,543 |
Noncontrolling interests | 9 |  |  | 7 |
Total stockholders’ equity | 51,080 |  |  | 49,550 |
Total liabilities and stockholders’ equity | $ | 79,897 |  |  | $ | 77,542 |

See the accompanying Notes to the Consolidated Condensed Financial Statements.
1

Table of Contents
DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
($ and shares in millions, except per share amounts)
(unaudited)

| Three-Month Period Ended |  | Nine-Month Period Ended |  |  |
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024 |  |  |
Sales | $ | 6,053 |  |  | $ | 5,798 |  |  | $ | 17,730 |  |  | $ | 17,337 |  |  |  |
Cost of sales | (2,530) |  |  | (2,397) |  |  | (7,173) |  |  | (7,021) |  |  |  |
Gross profit | 3,523 |  |  | 3,401 |  |  | 10,557 |  |  | 10,316 |  |  |  |
Operating costs: |  |  |  |  |  |  |  |  |  |
Selling, general and administrative expenses | (1,991) |  |  | (2,060) |  |  | (6,209) |  |  | (5,736) |  |  |  |
Research and development expenses | (378) |  |  | (383) |  |  | (1,160) |  |  | (1,142) |  |  |  |
Operating profit | 1,154 |  |  | 958 |  |  | 3,188 |  |  | 3,438 |  |  |  |
Nonoperating income (expense): |  |  |  |  |  |  |  |  |  |
Other income (expense), net | (14) |  |  | 102 |  |  | (135) |  |  | 7 |  |  |  |
Interest expense | (67) |  |  | (87) |  |  | (210) |  |  | (217) |  |  |  |
Interest income | 3 |  |  | 4 |  |  | 17 |  |  | 103 |  |  |  |
Earnings before income taxes | 1,076 |  |  | 977 |  |  | 2,860 |  |  | 3,331 |  |  |  |
Income taxes | (168) |  |  | (159) |  |  | (443) |  |  | (518) |  |  |  |
Net earnings | $ | 908 |  |  | $ | 818 |  |  | $ | 2,417 |  |  | $ | 2,813 |  |  |  |
Net earnings per common share: |  |  |  |  |  |  |  |  |  |
Basic | $ | 1.28 |  |  | $ | 1.13 |  |  | $ | 3.38 |  | (a) | $ | 3.83 |  |  |  |
Diluted | $ | 1.27 |  |  | $ | 1.12 |  |  | $ | 3.37 |  | (a) | $ | 3.80 |  | (a) |  |
Average common stock and common equivalent shares outstanding: |  |  |  |  |  |  |  |  |  |
Basic | 710.7 |  |  | 723.0 |  |  | 714.5 |  |  | 733.8 |  |  |  |
Diluted | 713.7 |  |  | 729.4 |  |  | 717.9 |  |  | 740.1 |  |  |  |

(a) Net earnings per common share amounts for the relevant three-month periods do not add to the nine-month period amount due to rounding.
See the accompanying Notes to the Consolidated Condensed Financial Statements.
2

Table of Contents
DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
($ in millions)
(unaudited)

| Three-Month Period Ended |  | Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Net earnings | $ | 908 |  |  | $ | 818 |  |  | $ | 2,417 |  |  | $ | 2,813 |
Other comprehensive income (loss), net of income taxes: |  |  |  |  |  |  |
Foreign currency translation adjustments | (71) |  |  | 1,216 |  |  | 2,406 |  |  | 389 |
Pension and postretirement plan benefit adjustments | 2 |  |  | 2 |  |  | 5 |  |  | 6 |
Cash flow hedge adjustments | 48 |  |  | 63 |  |  | 217 |  |  | 43 |
Total other comprehensive income (loss), net of income taxes | (21) |  |  | 1,281 |  |  | 2,628 |  |  | 438 |
Comprehensive income | $ | 887 |  |  | $ | 2,099 |  |  | $ | 5,045 |  |  | $ | 3,251 |

See the accompanying Notes to the Consolidated Condensed Financial Statements.
3

Table of Contents
DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY
($ in millions)
(unaudited)

| Three-Month Period Ended |  | Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Common stock: |  |  |  |  |  |  |
Balance, beginning and end of period | $ | 9 |  |  | $ | 9 |  |  | $ | 9 |  |  | $ | 9 |
Additional paid-in capital: |  |  |  |  |  |  |
Balance, beginning of period | $ | 16,960 |  |  | $ | 16,490 |  |  | $ | 16,727 |  |  | $ | 16,170 |
Common stock-based award activity | 116 |  |  | 151 |  |  | 349 |  |  | 468 |
Acquisition of controlling interests | — |  |  | — |  |  | — |  |  | 3 |
Balance, end of period | $ | 17,076 |  |  | $ | 16,641 |  |  | $ | 17,076 |  |  | $ | 16,641 |
Treasury stock: |  |  |  |  |  |  |
Balance, beginning of period | $ | (9,305) |  |  | $ | (6,684) |  |  | $ | (8,163) |  |  | $ | (2,019) |
Repurchase of common stock, including excise tax | (2,030) |  |  | (646) |  |  | (3,112) |  |  | (5,222) |
Common stock-based award activity | (9) |  |  | (7) |  |  | (69) |  |  | (96) |
Balance, end of period | $ | (11,344) |  |  | $ | (7,337) |  |  | $ | (11,344) |  |  | $ | (7,337) |
Retained earnings: |  |  |  |  |  |  |
Balance, beginning of period | $ | 45,239 |  |  | $ | 42,673 |  |  | $ | 44,188 |  |  | $ | 41,074 |
Net earnings | 908 |  |  | 818 |  |  | 2,417 |  |  | 2,813 |
Common stock dividends declared | (227) |  |  | (195) |  |  | (685) |  |  | (591) |
Balance, end of period | $ | 45,920 |  |  | $ | 43,296 |  |  | $ | 45,920 |  |  | $ | 43,296 |
Accumulated other comprehensive income (loss): |  |  |  |  |  |  |
Balance, beginning of period | $ | (569) |  |  | $ | (2,591) |  |  | $ | (3,218) |  |  | $ | (1,748) |
Other comprehensive income (loss) | (21) |  |  | 1,281 |  |  | 2,628 |  |  | 438 |
Balance, end of period | $ | (590) |  |  | $ | (1,310) |  |  | $ | (590) |  |  | $ | (1,310) |
Noncontrolling interests: |  |  |  |  |  |  |
Balance, beginning of period | $ | 8 |  |  | $ | 5 |  |  | $ | 7 |  |  | $ | 4 |
Change in noncontrolling interests | 1 |  |  | 1 |  |  | 2 |  |  | 2 |
Balance, end of period | $ | 9 |  |  | $ | 6 |  |  | $ | 9 |  |  | $ | 6 |
Total stockholders’ equity, end of period | $ | 51,080 |  |  | $ | 51,305 |  |  | $ | 51,080 |  |  | $ | 51,305 |

See the accompanying Notes to the Consolidated Condensed Financial Statements.
4

Table of Contents
DANAHER CORPORATION AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
($ in millions)
(unaudited)

| Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024
Cash flows from operating activities: |  |  |
Net earnings | $ | 2,417 |  |  | $ | 2,813 |
Noncash items: |  |  |
Depreciation | 555 |  |  | 534 |
Amortization of intangible assets | 1,269 |  |  | 1,223 |
Amortization of acquisition-related inventory fair value step-up | — |  |  | 25 |
Stock-based compensation expense | 235 |  |  | 231 |
Investment losses and pretax gain on sale of product line | 140 |  |  | (7) |
Impairment charges | 548 |  |  | 222 |
Change in trade accounts receivable, net | (65) |  |  | 482 |
Change in inventories | (242) |  |  | (117) |
Change in trade accounts payable | (134) |  |  | (186) |
Change in prepaid expenses and other assets | (53) |  |  | 299 |
Change in accrued expenses and other liabilities | (371) |  |  | (850) |
Net cash provided by operating activities | 4,299 |  |  | 4,669 |
Cash flows from investing activities: |  |  |
Cash paid for acquisitions | — |  |  | (525) |
Payments for additions to property, plant and equipment | (785) |  |  | (876) |
Proceeds from sales of property, plant and equipment | 10 |  |  | 12 |
Payments for purchases of investments | (79) |  |  | (188) |
Proceeds from sales of investments | 12 |  |  | 251 |
Proceeds from sale of product line | 9 |  |  | — |
All other investing activities | 21 |  |  | 39 |
Total cash used in investing activities | (812) |  |  | (1,287) |
Cash flows from financing activities: |  |  |
Proceeds from the issuance of common stock in connection with stock-based compensation, net | 39 |  |  | 143 |
Payment of dividends | (652) |  |  | (573) |
Net proceeds from borrowings (maturities of 90 days or less) | 22 |  |  | 1 |
Borrowings (maturities longer than 90 days) | 4 |  |  | — |
Repayments of borrowings (maturities longer than 90 days) | (500) |  |  | (974) |
Payments for repurchase of common stock | (3,088) |  |  | (5,170) |
All other financing activities | (108) |  |  | (120) |
Total cash used in financing activities | (4,283) |  |  | (6,693) |
Effect of exchange rate changes on cash and equivalents | 246 |  |  | 74 |
Net change in cash and equivalents | (550) |  |  | (3,237) |
Beginning balance of cash and equivalents | 2,078 |  |  | 5,864 |
Ending balance of cash and equivalents | $ | 1,528 |  |  | $ | 2,627 |
Supplemental disclosures: |  |  |
Cash interest payments | $ | 231 |  |  | $ | 280 |
Cash income tax payments | 808 |  |  | 933 |

See the accompanying Notes to the Consolidated Condensed Financial Statements.
5

Table of Contents
DANAHER CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(unaudited)
NOTE 1. GENERAL
The Consolidated Condensed Financial Statements included herein have been prepared by Danaher Corporation (“Danaher” or the “Company”) without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). In this quarterly report, the terms “Danaher” or the “Company” refer to Danaher Corporation, Danaher Corporation and its consolidated subsidiaries, or the consolidated subsidiaries of Danaher Corporation, as the context requires. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to SEC rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The Consolidated Condensed Financial Statements included herein should be read in conjunction with the financial statements as of and for the year ended December 31, 2024 and the Notes thereto included in the Company’s 2024 Annual Report on Form 10-K filed on February 20, 2025 (the “2024 Annual Report”).
In the opinion of the Company, the accompanying financial statements contain all adjustments (consisting of only normal recurring accruals) necessary to present fairly the financial position of the Company as of September 26, 2025 and December 31, 2024, its results of operations for the three and nine-month periods ended September 26, 2025 and September 27, 2024 and its cash flows for each of the nine-month periods then ended.
There have been no changes to the Company’s significant accounting policies described in the Company’s 2024 Annual Report that have a material impact on the Company’s Consolidated Condensed Financial Statements and the related Notes. Reclassifications of certain prior year amounts have been made to conform to the current year presentation.
Accounting Standards Recently Adopted—In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Improvements to Reportable Segment Disclosures. The ASU requires additional disclosures about reportable segments’ significant expenses on an interim and annual basis. The Company adopted the ASU effective January 1, 2024 on a retrospective basis. Refer to Note 5 for additional segment disclosures.
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures. The ASU expands disclosures in the income tax rate reconciliations table and cash taxes paid. The Company adopted the ASU effective January 1, 2025. This accounting standard will increase the tax disclosures in the Company’s annual reporting but has no impact on reported income tax expense or related tax assets or liabilities.
Accounting Standards Not Yet Adopted—In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses. The ASU requires disclosure of disaggregated information about certain income statement expenses, including specific expense categories. The ASU is effective for annual periods beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. This accounting standard will increase disclosures in the Company’s annual and interim reporting when adopted.
In July 2025, the FASB issued ASU 2025-05, Measurement of Credit Loss for Accounts Receivable and Contract Assets. The ASU provides a practical expedient for the calculation of current expected credit losses for current accounts receivable and contract assets, allowing entities to assume that current conditions as of the balance sheet date will persist through the forecast period. The ASU is effective for interim and annual reporting periods beginning after December 15, 2025. The Company is assessing the impact of the ASU on its consolidated financial statements and related disclosures.
In September 2025, the FASB issued ASU 2025-06, Targeted Improvements to the Accounting for Internal-Use Software. The ASU updates the requirements for capitalization of internal-use software, removing all reference to prescriptive and sequential software development stages. The ASU is effective for annual periods beginning after December 15, 2027 and for interim periods within those fiscal years. The Company is assessing the impact of the ASU on its consolidated financial statements and related disclosures.
Prepaid Expenses and Other Current Assets—Prepaid expenses and other current assets primarily result from advance payments to vendors for goods and services which are capitalized until the related goods are received or services are performed and advance payments to tax authorities. The Company’s prepaid expenses and other current assets balances as of September 26, 2025 and December 31, 2024 are primarily comprised of prepaid expenses of $639 million and $620 million, respectively, and taxes receivable for income and other taxes and deferred tax assets of $920 million and $853 million, respectively.
6

Table of Contents
Operating Leases—As of September 26, 2025 and December 31, 2024, operating lease right-of-use assets where the Company was the lessee were approximately $1.2 billion and $1.1 billion, respectively, and are included within other long-term assets in the accompanying Consolidated Condensed Balance Sheets. The associated operating lease liabilities were approximately $1.3 billion and $1.1 billion as of September 26, 2025 and December 31, 2024, respectively, and are included in accrued expenses and other liabilities and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets.
U.S. Pension Plan Buy-In—In September 2025, the Company entered into a $349 million insurance buy-in contract for a portion of the benefit obligations under the U.S. defined benefit pension plan, which was funded from existing pension plan assets without an adjustment to the benefit obligations. Insurance buy-in contracts are annuity contracts that are expected to provide an income stream to cover the cash flows associated with future contracted payments for the plan population. However, the benefit obligation remains with the plan and the Company. This contract is issued by a third-party insurance company that has no affiliation with the Company or the plan.
NOTE 2. ACQUISITIONS
For a description of the Company’s acquisition activity for the year ended December 31, 2024, reference is made to the financial statements as of and for the year ended December 31, 2024 and Note 2 thereto included in the Company’s 2024 Annual Report. There were no acquisitions during the nine-month period ended September 26, 2025.
The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or expand the Company’s portfolio into a new and attractive business area. The Company has completed a number of acquisitions that have been accounted for as purchases and have resulted in the recognition of goodwill in the Company’s financial statements. This goodwill arises because the purchase prices for these businesses exceed the fair value of acquired identifiable net assets due to the purchase prices reflecting a number of factors including the future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at which similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the Company acquired the businesses, the avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and profitable businesses and the complementary strategic fit and resulting synergies these businesses bring to existing operations.
The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains the information used for the purchase price allocation during due diligence and through other sources. In the months after closing, as the Company obtains additional information about the acquired assets and liabilities, including through tangible and intangible asset appraisals, and learns more about the newly acquired business, it is able to refine the estimates of fair value and more accurately allocate the purchase price. The fair values of acquired intangibles are determined based on estimates and assumptions that are deemed reasonable by the Company. Significant assumptions include the discount rates and certain assumptions that form the basis of the forecasted results of the acquired business including earnings before interest, taxes, depreciation and amortization (“EBITDA”), revenue, revenue growth rates, royalty rates and technology obsolescence rates. These assumptions are forward looking and could be affected by future economic and market conditions. The Company engages third-party valuation specialists who review the Company’s critical assumptions and calculations of the fair value of acquired intangible assets in connection with significant acquisitions. Only facts and circumstances that existed as of the acquisition date are considered for subsequent adjustment.
Pro Forma Financial Information
The unaudited pro forma information for the periods set forth below gives effect to the 2024 acquisitions as if they had occurred as of the beginning of the comparable prior annual reporting period, including the results from operations for the acquired businesses as well as the impact of assumed financing of the transaction and the impact of the purchase price allocation (including the amortization of acquired intangible assets). The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions, except per share amounts):

| Three-Month Period Ended |  | Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Sales | $ | 6,053 |  |  | $ | 5,799 |  |  | $ | 17,730 |  |  | $ | 17,381 |
Net earnings | 908 |  |  | 818 |  |  | 2,417 |  |  | 2,821 |
Diluted net earnings per common share | 1.27 |  |  | 1.12 |  |  | 3.37 |  |  | 3.81 |

The nine-month period ended September 27, 2024 unaudited pro forma net earnings were adjusted to exclude the pretax impact of a $25 million nonrecurring acquisition date fair value adjustment to inventory.
7

Table of Contents
NOTE 3. NET EARNINGS PER COMMON SHARE
Basic net earnings per common share (“EPS”) is calculated by taking net earnings divided by the weighted average number of common shares outstanding for the applicable period. Diluted net EPS is computed by taking net earnings increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued and reduced by the number of shares the Company could have repurchased with the proceeds from the issuance of the potentially dilutive shares. For the three-month periods ended September 26, 2025 and September 27, 2024, approximately 6.9 million and 305 thousand options, respectively, and for the nine-month periods ended September 26, 2025 and September 27, 2024, approximately 6.8 million and 1.2 million options, respectively, to purchase shares were excluded from the diluted EPS calculation, as the impact of their inclusion would have been anti-dilutive. Basic and diluted EPS are computed independently for each quarter and year-to-date period, and each period involves the use of different weighted average share count figures. As a result, and after factoring in the effect of rounding to the nearest cent per share, the sum of prior quarterly EPS figures may not equal year-to-date EPS.
Information related to the calculation of net earnings per common share is summarized as follows ($ and shares in millions, except per share amounts):

| Three-Month Period Ended |  | Nine-Month Period Ended |
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024 |
Numerator: |  |  |  |  |  |  |  |
Net earnings | $ | 908 |  |  | $ | 818 |  |  | $ | 2,417 |  |  | $ | 2,813 |  |
Denominator: |  |  |  |  |  |  |  |
Weighted average common shares outstanding used in Basic EPS | 710.7 |  |  | 723.0 |  |  | 714.5 |  |  | 733.8 |  |
Incremental common shares from: |  |  |  |  |  |  |  |
Assumed exercise of dilutive options and vesting of dilutive restricted stock units (“RSUs”) and performance stock units (“PSUs”) | 3.0 |  |  | 6.4 |  |  | 3.4 |  |  | 6.3 |  |
Weighted average common shares outstanding used in Diluted EPS | 713.7 |  |  | 729.4 |  |  | 717.9 |  |  | 740.1 |  |
Basic EPS | $ | 1.28 |  |  | $ | 1.13 |  |  | $ | 3.38 |  |  | $ | 3.83 |  |
Diluted EPS | $ | 1.27 |  |  | $ | 1.12 |  |  | $ | 3.37 |  |  | $ | 3.80 |  |

8

Table of Contents
NOTE 4. REVENUE
The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three and nine-month periods ended September 26, 2025 and September 27, 2024 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenue.

| Biotechnology |  | Life Sciences |  | Diagnostics |  | Total
For the Three-Month Period Ended September 26, 2025: |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |
North America(a) | $ | 624 |  |  | $ | 728 |  |  | $ | 1,228 |  |  | $ | 2,580 |
Western Europe | 587 |  |  | 392 |  |  | 417 |  |  | 1,396 |
Other developed markets(b) | 89 |  |  | 130 |  |  | 97 |  |  | 316 |
High-growth markets(c) | 498 |  |  | 542 |  |  | 721 |  |  | 1,761 |
Total | $ | 1,798 |  |  | $ | 1,792 |  |  | $ | 2,463 |  |  | $ | 6,053 |
Revenue type: |  |  |  |  |  |  |
Recurring | $ | 1,590 |  |  | $ | 1,216 |  |  | $ | 2,211 |  |  | $ | 5,017 |
Nonrecurring | 208 |  |  | 576 |  |  | 252 |  |  | 1,036 |
Total | $ | 1,798 |  |  | $ | 1,792 |  |  | $ | 2,463 |  |  | $ | 6,053 |
For the Three-Month Period Ended September 27, 2024: |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |
North America(a) | $ | 503 |  |  | $ | 796 |  |  | $ | 1,157 |  |  | $ | 2,456 |
Western Europe | 587 |  |  | 365 |  |  | 368 |  |  | 1,320 |
Other developed markets(b) | 78 |  |  | 120 |  |  | 101 |  |  | 299 |
High-growth markets(c) | 485 |  |  | 501 |  |  | 737 |  |  | 1,723 |
Total | $ | 1,653 |  |  | $ | 1,782 |  |  | $ | 2,363 |  |  | $ | 5,798 |
Revenue type: |  |  |  |  |  |  |
Recurring | $ | 1,422 |  |  | $ | 1,228 |  |  | $ | 2,127 |  |  | $ | 4,777 |
Nonrecurring | 231 |  |  | 554 |  |  | 236 |  |  | 1,021 |
Total | $ | 1,653 |  |  | $ | 1,782 |  |  | $ | 2,363 |  |  | $ | 5,798 |

9

Table of Contents

| Biotechnology |  | Life Sciences |  | Diagnostics |  | Total
For the Nine-Month Period Ended September 26, 2025: |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |
North America(a) | $ | 1,779 |  |  | $ | 2,211 |  |  | $ | 3,610 |  |  | $ | 7,600 |
Western Europe | 1,861 |  |  | 1,164 |  |  | 1,222 |  |  | 4,247 |
Other developed markets(b) | 235 |  |  | 371 |  |  | 282 |  |  | 888 |
High-growth markets(c) | 1,385 |  |  | 1,503 |  |  | 2,107 |  |  | 4,995 |
Total | $ | 5,260 |  |  | $ | 5,249 |  |  | $ | 7,221 |  |  | $ | 17,730 |
Revenue type: |  |  |  |  |  |  |
Recurring | $ | 4,741 |  |  | $ | 3,566 |  |  | $ | 6,496 |  |  | $ | 14,803 |
Nonrecurring | 519 |  |  | 1,683 |  |  | 725 |  |  | 2,927 |
Total | $ | 5,260 |  |  | $ | 5,249 |  |  | $ | 7,221 |  |  | $ | 17,730 |
For the Nine-Month Period Ended September 27, 2024: |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |
North America(a) | $ | 1,624 |  |  | $ | 2,362 |  |  | $ | 3,536 |  |  | $ | 7,522 |
Western Europe | 1,700 |  |  | 1,111 |  |  | 1,154 |  |  | 3,965 |
Other developed markets(b) | 238 |  |  | 361 |  |  | 295 |  |  | 894 |
High-growth markets(c) | 1,328 |  |  | 1,463 |  |  | 2,165 |  |  | 4,956 |
Total | $ | 4,890 |  |  | $ | 5,297 |  |  | $ | 7,150 |  |  | $ | 17,337 |
Revenue type: |  |  |  |  |  |  |
Recurring | $ | 4,209 |  |  | $ | 3,628 |  |  | $ | 6,424 |  |  | $ | 14,261 |
Nonrecurring | 681 |  |  | 1,669 |  |  | 726 |  |  | 3,076 |
Total | $ | 4,890 |  |  | $ | 5,297 |  |  | $ | 7,150 |  |  | $ | 17,337 |

(a) The Company defines North America as the United States and Canada.
(b) The Company defines other developed markets as all the markets of the world that are not North America, Western Europe or high-growth markets.
(c) The Company defines high-growth markets as developing markets of the world experiencing accelerated growth, over extended periods, in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that are not high-growth markets.
The Company’s products and services primarily consist of life sciences research, biopharmaceutical drug production and medical diagnostic products and services. The Company sells equipment to customers as well as consumables, software and services, some of which customers purchase on a recurring basis. Consumables sold for use with the equipment sold by the Company are typically critical to the use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s operating cycle. Examples of these consumables include reagents used in diagnostic tests, chromatography resins used for research and bioprocessing and filters used in filtration, separation and purification processes. Additionally, some of the Company’s consumables are used on a standalone basis, such as custom nucleic acids, genomics solutions, antibodies and immunoassays. The Company separates its goods and services between those typically sold to a customer on a recurring basis and those typically sold to a customer on a nonrecurring basis. Recurring revenue includes revenue from consumables (both used with Company equipment and used on a standalone basis), services and operating-type leases (“OTLs”). Nonrecurring revenue includes sales of equipment and sales-type leases (“STLs”). OTLs and STLs are included in the above revenue amounts. For the three-month periods ended September 26, 2025 and September 27, 2024, lease revenue was $112 million and $93 million, respectively. For the nine-month periods ended September 26, 2025 and September 27, 2024, lease revenue was $343 million and $287 million, respectively.
Remaining performance obligations related to Topic 606, Revenue from Contracts with Customers, represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. As of September 26, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $4.9 billion. The Company expects to recognize revenue on approximately 46% of the remaining performance obligations over the next 12 months, 28% over the subsequent 12 months, and the remainder recognized thereafter.
10

Table of Contents
The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (“contract assets”) and deferred revenue, customer deposits and billings in excess of revenue recognized (“contract liabilities”) on the accompanying Consolidated Condensed Balance Sheets. Contract assets and liabilities are reported on a net basis (on a contract-by-contract basis) in the accompanying Consolidated Condensed Balance Sheets at the end of each reporting period.
The Company often receives cash payments from customers in advance of the Company’s performance, resulting in contract liabilities that are classified as either current or long-term in the accompanying Consolidated Condensed Balance Sheets based on the timing of when the Company expects to recognize revenue. As of September 26, 2025 and December 31, 2024, contract liabilities were approximately $1.6 billion and $1.5 billion, respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. The increase in the contract liability balance during the nine-month period ended September 26, 2025 was primarily a result of cash payments received in advance of satisfying performance obligations, partially offset by amounts recognized as revenue. Revenue recognized during the nine-month periods ended September 26, 2025 and September 27, 2024 that was included in the contract liability balance on December 31, 2024 and December 31, 2023 was $973 million and approximately $1.1 billion, respectively.
NOTE 5. SEGMENT INFORMATION
The Company operates and reports its results in three separate business segments consisting of the Biotechnology, Life Sciences and Diagnostics segments. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes. The identifiable assets by segment are those used in each segment’s operations. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals.
The chief operating decision maker (“CODM”) uses segment sales and operating profit to allocate resources (including employees and financial or capital resources), predominantly through the annual budget process, to evaluate and assess the performance of the segments and to evaluate the performance of certain employees for the determination of compensation. The CODM reviews forecast-to-actual variances in segment sales and operating profit on a monthly basis when making decisions about allocating capital and personnel to the segments.
The table below reconciles segment sales to segment operating profit with the expense categories presented reflecting the expenses that the Company has determined to be significant segment expenses. Significant segment expenses are the expense category details regularly provided to the CODM to allocate resources to the segments and to evaluate segment performance. Detailed segment data for the three and nine-month periods ended September 26, 2025 and September 27, 2024 is as follows ($ in millions):

| Biotechnology |  | Life Sciences |  | Diagnostics |  | Other(a) |  | Total |  |  |  |
For the Three-Month Period Ended September 26, 2025: |  |  |  |  |  |  |  |  |  |  |  |  |
Sales | $ | 1,798 |  |  | $ | 1,792 |  |  | $ | 2,463 |  |  | $ | — |  |  | $ | 6,053 |  |  |  |  |
Less: |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation | (38) |  |  | (47) |  |  | (101) |  |  | (3) |  |  | (189) |  |  |  |  |
Amortization of intangible assets | (231) |  |  | (154) |  |  | (48) |  |  | — |  |  | (433) |  |  |  |  |
Impairments(b) | (86) |  |  | — |  |  | (15) |  |  | — |  |  | (101) |  |  |  |  |
Other segment expenses(c) | (1,091) |  |  | (1,369) |  |  | (1,634) |  |  | (82) |  |  | (4,176) |  |  |  |  |
Operating profit | $ | 352 |  |  | $ | 222 |  |  | $ | 665 |  |  | $ | (85) |  |  | $ | 1,154 |  |  |  |  |
For the Three-Month Period Ended September 27, 2024: |  |  |  |  |  |  |  |  |  |  |  |  |
Sales | $ | 1,653 |  |  | $ | 1,782 |  |  | $ | 2,363 |  |  | $ | — |  |  | $ | 5,798 |  |  |  |  |
Less: |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation | (36) |  |  | (44) |  |  | (95) |  |  | (2) |  |  | (177) |  |  |  |  |
Amortization of intangible assets | (218) |  |  | (147) |  |  | (49) |  |  | — |  |  | (414) |  |  |  |  |
Impairments(b) | — |  |  | (222) |  |  | — |  |  | — |  |  | (222) |  |  |  |  |
Other segment expenses(c) | (1,009) |  |  | (1,334) |  |  | (1,604) |  |  | (80) |  |  | (4,027) |  |  |  |  |
Operating profit (loss) | $ | 390 |  |  | $ | 35 |  |  | $ | 615 |  |  | $ | (82) |  |  | $ | 958 |  |  |  |  |

11

Table of Contents

| Biotechnology |  | Life Sciences |  | Diagnostics |  | Other(a) |  | Total
For the Nine-Month Period Ended September 26, 2025: |  |  |  |  |  |  |  |  |
Sales | $ | 5,260 |  |  | $ | 5,249 |  |  | $ | 7,221 |  |  | $ | — |  |  | $ | 17,730 |
Less: |  |  |  |  |  |  |  |  |
Depreciation | (110) |  |  | (137) |  |  | (301) |  |  | (7) |  |  | (555) |
Amortization of intangible assets | (672) |  |  | (453) |  |  | (144) |  |  | — |  |  | (1,269) |
Impairments(b) | (101) |  |  | (432) |  |  | (15) |  |  | — |  |  | (548) |
Other segment expenses(c) | (3,053) |  |  | (4,043) |  |  | (4,824) |  |  | (250) |  |  | (12,170) |
Operating profit | $ | 1,324 |  |  | $ | 184 |  |  | $ | 1,937 |  |  | $ | (257) |  |  | $ | 3,188 |
For the Nine-Month Period Ended September 27, 2024: |  |  |  |  |  |  |  |  |
Sales | $ | 4,890 |  |  | $ | 5,297 |  |  | $ | 7,150 |  |  | $ | — |  |  | $ | 17,337 |
Less: |  |  |  |  |  |  |  |  |
Depreciation | (113) |  |  | (123) |  |  | (292) |  |  | (6) |  |  | (534) |
Amortization of intangible assets | (650) |  |  | (428) |  |  | (145) |  |  | — |  |  | (1,223) |
Impairments(b) | — |  |  | (222) |  |  | — |  |  | — |  |  | (222) |
Other segment expenses(c) | (2,950) |  |  | (4,021) |  |  | (4,712) |  |  | (237) |  |  | (11,920) |
Operating profit (loss) | $ | 1,177 |  |  | $ | 503 |  |  | $ | 2,001 |  |  | $ | (243) |  |  | $ | 3,438 |

(a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance.
(b) For information on the impairments, refer to Note 8.
(c) Other segment expenses for each reportable segment include cost of sales, selling, general and administrative (“SG&A”) expenses and research and development (“R&D”) expenses, excluding in each case depreciation, amortization of intangible assets and impairments. Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses.
The following table presents identifiable assets as of September 26, 2025 and December 31, 2024 ($ in millions):

| September 26, 2025 |  | December 31, 2024
Identifiable assets: |  |  |
Biotechnology | $ | 37,296 |  |  | $ | 34,605 |
Life Sciences | 23,179 |  |  | 23,211 |
Diagnostics | 14,653 |  |  | 14,204 |
Other | 4,769 |  |  | 5,522 |
Total | $ | 79,897 |  |  | $ | 77,542 |

The following table presents capital expenditures for the three and nine-month periods ended September 26, 2025 and September 27, 2024 ($ in millions):

| Three-Month Period Ended |  | Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Capital expenditures: |  |  |  |  |  |  |
Biotechnology | $ | 94 |  |  | $ | 117 |  |  | $ | 255 |  |  | $ | 330 |
Life Sciences | 40 |  |  | 52 |  |  | 129 |  |  | 162 |
Diagnostics | 157 |  |  | 129 |  |  | 397 |  |  | 382 |
Other | 1 |  |  | — |  |  | 4 |  |  | 2 |
Total | $ | 292 |  |  | $ | 298 |  |  | $ | 785 |  |  | $ | 876 |

12

Table of Contents
NOTE 6. INCOME TAXES
The following table summarizes the Company’s effective tax rate:

| Three-Month Period Ended |  | Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Effective tax rate | 15.6 | % |  | 16.3 | % |  | 15.5 | % |  | 15.6 | %

The Company operates globally, including in certain jurisdictions with lower tax rates than the United States (“U.S.”) federal statutory rate. Therefore, the impact of Danaher’s global operations and benefits from tax credits and incentives contributes to a lower effective tax rate compared to the U.S. federal statutory tax rate. For each period presented, the effective tax rate differs from the U.S. federal statutory rate of 21.0% principally due to the impact of the Company’s global operations, research tax credits, foreign-derived intangible income and aggregate net discrete benefits or charges.
For the three-month period ended September 26, 2025, the effective tax rate was reduced by the tax effect from intangible asset impairments in jurisdictions with higher statutory tax rates than the Company’s effective tax rate, which reduced the effective tax rate by 1.3%. There was no net discrete tax charge in the three-month period, as a valuation allowance recorded on certain foreign operating losses was offset by benefits from the remeasurement of deferred taxes in a jurisdiction which enacted a tax rate change.
For the three-month period ended September 27, 2024, the effective tax rate included the tax effect from an intangible asset impairment in a jurisdiction with a higher statutory tax rate than the Company’s effective tax rate, which reduced the effective tax rate by 1.4%. There was no net discrete tax benefit in the three-month period, as excess tax benefits from stock-based compensation were offset by other discrete tax charges.
For the nine-month period ended September 26, 2025, the effective tax rate was reduced by the tax effect from intangible asset impairments in jurisdictions with higher statutory tax rates than the Company’s effective tax rate, the remeasurement of deferred taxes in a jurisdiction which enacted a tax rate change and the release of reserves for uncertain tax positions due to the expiration of statutes of limitations, partially offset by a valuation allowance recorded on certain foreign operating losses and changes in uncertain tax positions. The net impact reduced the effective tax rate by 1.2%.
For the nine-month period ended September 27, 2024, aggregate net discrete tax benefits reduced the effective tax rate by 1.4% and related primarily to excess tax benefits from stock-based compensation, release of reserves for uncertain tax positions due to the expiration of statutes of limitation and changes in estimates associated with prior period uncertain tax positions. The effective tax rate for this period also included the tax effect from an intangible asset impairment, which reduced the effective tax rate by 0.5%.
In the fourth quarter of 2022, the U.S. Internal Revenue Service (“IRS”) proposed significant adjustments to the Company’s taxable income for the years 2016 through 2018 with respect to the deferral of tax on certain premium income related to the Company’s self-insurance programs. For income tax purposes, the recognition of premium income has been deferred in accordance with U.S. tax laws related to insurance. The proposed adjustments would have increased the Company’s taxable income over the 2016 through 2018 periods by approximately $2.5 billion. In the first quarter of 2023, the Company settled these proposed adjustments with the IRS, although the audit is still open with respect to other matters for the 2016 through 2018 period. The impact of the settlement with respect to the Company’s self-insurance policies was not material to the Company’s financial statements, including cash flows and the effective tax rate. As the settlement with the IRS was specific to the audit period, the settlement does not preclude the IRS from proposing similar adjustments to the Company’s self-insurance programs with respect to periods after 2018. Management believes the positions the Company has taken in its U.S. tax returns are in accordance with the relevant tax laws.
On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted, which includes permanent extensions of most expiring Tax Cuts and Jobs Act provisions as well as international tax changes. The application of the OBBBA to the Company did not have a material impact on its financial statements during the three-month period ended September 26, 2025.
For a description of the Company’s significant tax matters, reference is made to the financial statements as of and for the year ended December 31, 2024 and Note 7 thereto included in the Company’s 2024 Annual Report.
13

Table of Contents
NOTE 7. OTHER INCOME (EXPENSE), NET
The following sets forth the components of the Company’s other income (expense), net ($ in millions):

| Three-Month Period Ended |  | Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Other components of net periodic benefit costs | $ | 1 |  |  | $ | (1) |  |  | $ | 5 |  |  | $ | — |
Investment gains (losses): |  |  |  |  |  |  |
Realized investment gains (losses) | — |  |  | 198 |  |  | (72) |  |  | 159 |
Unrealized investment gains (losses) | (15) |  |  | (95) |  |  | (77) |  |  | (152) |
Total investment gains (losses) | (15) |  |  | 103 |  |  | (149) |  |  | 7 |
Gain on sale of product line | — |  |  | — |  |  | 9 |  |  | — |
Total other income (expense), net | $ | (14) |  |  | $ | 102 |  |  | $ | (135) |  |  | $ | 7 |

Other Components of Net Periodic Benefit Costs
The Company disaggregates the service cost component of net periodic benefit costs of noncontributory defined benefit pension plans and other postretirement employee benefit plans. The service cost component is presented in cost of goods sold and SG&A expenses. The other components of net periodic benefit costs are presented in other income (expense), net. These other components of net periodic benefit costs include the assumed rate of return on plan assets, partially offset by amortization of actuarial losses and interest.
Investment Gains (Losses)
For investments in equity securities without readily available fair values, the Company has elected the measurement alternative to record these investments at cost and to adjust for impairments and observable price changes with a same or similar security from the same issuer within net earnings (the “Fair Value Alternative”). Additionally, the Company is a limited partner in partnerships that invest primarily in early-stage companies. While the partnerships record these investments at fair value, the Company’s investments in the partnerships are accounted for under the equity method of accounting. The investment gains (losses) include realized and unrealized gains and losses related to changes in the fair value of the Company’s investments in equity securities and the Company’s equity in earnings of the partnerships that reflect the changes in fair value of the investments of the partnerships, and related management fees and operating expenses. In the third quarter of 2024, the Company sold a portion of its shares of an equity method investment and recorded a realized investment gain of $180 million ($135 million after-tax) for the three and nine-month periods ended September 27, 2024.
Gain on Sale of Product Line
During the nine-month period ended September 26, 2025, the Company divested a product line for a cash purchase price of $9 million and recognized a pretax gain on sale of $9 million ($7 million after-tax). The divested product line generated revenues of approximately $50 million in the Diagnostics segment in 2024. The divestiture of this product line did not represent a strategic shift with a major effect on the Company’s operations and financial results and therefore is not reported as a discontinued operation.
NOTE 8. GOODWILL AND OTHER INTANGIBLE ASSETS
The following is a rollforward of the Company’s goodwill ($ in millions):

Balance, December 31, 2024 | $ | 40,497 |
Adjustments due to finalization of purchase price allocations | 9 |
Foreign currency translation and other | 2,442 |
Balance, September 26, 2025 | $ | 42,948 |

The carrying value of goodwill by segment is summarized as follows ($ in millions):

| September 26, 2025 |  | December 31, 2024
Biotechnology | $ | 23,145 |  |  | $ | 21,437 |
Life Sciences | 12,837 |  |  | 12,305 |
Diagnostics | 6,966 |  |  | 6,755 |
Total | $ | 42,948 |  |  | $ | 40,497 |

14

Table of Contents
The Company reviews identified intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable.
During the third quarter of 2024, the Company concluded that it had an impairment indicator for an indefinite-lived trade name within the genomics consumable business included in the Life Sciences segment, primarily as a result of softness in the genomics market, including but not limited to the discontinuation of certain drug development programs announced in the third quarter of 2024, weaker demand at some of the business’s larger customers as well as reduced demand due to the reprioritization of drug development programs at other customers. The Company engaged a third-party valuation specialist to assist in the valuation of the trade name using a relief from royalty method of valuation. The significant assumptions in the relief from royalty method included, but were not limited to, revenue, revenue growth rates, planned use of the trade name, royalty rates and discount rates. The Company recorded a noncash impairment charge of $222 million pretax ($169 million after-tax) related to the trade name for the three and nine-month periods ended September 27, 2024, which is included in selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings.
During the second quarter of 2025, the Company decided to reorganize and integrate certain businesses within its Life Sciences segment to better serve the Company’s customers in new market segments and to respond to current market conditions. As a result of these plans, the Company concluded that the same indefinite-lived trade name within the genomics consumables business was no longer considered to be indefinite-lived, resulting in an impairment indicator. The Company engaged a third-party valuation specialist to assist in the valuation of the trade name using a relief from royalty method of valuation. The Company recorded a noncash impairment charge of $432 million pretax ($328 million after-tax) related to the trade name for the nine-month period ended September 26, 2025, which is included in selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings. The amount of the impairment was primarily attributable to the conclusion that the trade name was no longer indefinite-lived, as well as current lower levels of demand in the genomics market, including at emerging biotechnology customers and at two large customers. After recognition of the impairment in the second quarter of 2025, the remaining net book value of the trade name was $76 million and will be amortized over the asset’s remaining useful life of eight years. The Company continues to monitor for any changes to the business performance or key assumptions.
In connection with both trade name impairments mentioned above, the Company also tested the related long-lived asset group and the related reporting unit goodwill for impairment, and in each case the Company identified no impairment.
During the third quarter of 2025, the Company identified impairment triggers for certain technology assets, a trade name and other intangible assets in the Biotechnology and Diagnostics segments. In the three and nine-month periods ended September 26, 2025, the Company recorded impairment charges of $101 million related to these long-lived assets, which is included in selling, general and administrative expenses in the accompanying Consolidated Condensed Statements of Earnings. Additionally, during the nine-month period ended September 26, 2025, the Company recorded a $15 million impairment related to a facility in the Biotechnology segment.
The reorganization of the Life Sciences segment resulted in a change to the businesses included in two of the Company’s five reporting units for goodwill beginning at the start of the third quarter of 2025. The Company used the relative fair value method to reallocate goodwill between the impacted reporting units within the Life Sciences segment. The Company performed the quantitative goodwill impairment analysis immediately prior to and following the change in the reporting units. As of the date of the impairment tests, the carrying value of the goodwill included in each individual reporting unit ranged from approximately $1.2 billion to $23.1 billion for both the previous reporting units and for the current reporting units (after the changes within Life Sciences). No impairments of goodwill were identified in either of the impairment evaluations before or immediately after the change in reporting units. The factors used by management in its impairment analysis are inherently subject to uncertainty. If actual results are not consistent with management’s estimates and assumptions, goodwill and other intangible assets may not be recoverable and a charge would need to be taken against net earnings.
The Company will continue to review goodwill and other intangible assets for impairment when events or changes in circumstances, including evolving market conditions and regulatory environment, indicate related carrying amounts may not be recoverable.
NOTE 9. FAIR VALUE MEASUREMENTS
Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by,
15

Table of Contents
observable market data through correlation. Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety.
A summary of financial assets that are measured at fair value on a recurring basis were as follows ($ in millions):

| Balance |  | Quoted Prices in Active Market (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
| September 26, 2025 |  | December 31, 2024 |  | September 26, 2025 |  | December 31, 2024 |  | September 26, 2025 |  | December 31, 2024 |  | September 26, 2025 |  | December 31, 2024
Assets: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investment in equity securities | $ | 194 |  |  | $ | 218 |  |  | $ | — |  |  | $ | 3 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Cross-currency swap derivative contracts | 129 |  |  | 415 |  |  | — |  |  | — |  |  | 129 |  |  | 415 |  |  | — |  |  | — |
Liabilities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cross-currency swap derivative contracts | 44 |  |  | — |  |  | — |  |  | — |  |  | 44 |  |  | — |  |  | — |  |  | — |

The Company’s investments in equity securities consist of investments in publicly traded equity securities and investments in non-marketable equity securities. The publicly traded securities are classified as Level 1 in the fair value hierarchy as they are measured based on quotes in active markets. For the non-marketable equity securities, the Company estimates the fair value of the investments using the Fair Value Alternative. The Company’s investments in these equity securities are not classified in the fair value hierarchy due to the use of these measurement methods. Additionally, the Company is a limited partner in partnerships that invest primarily in early-stage companies. While the partnerships record these investments at fair value, the Company’s investments in the partnerships are accounted for under the equity method of accounting and are not subject to the fair value measurement disclosures noted above. As of both September 26, 2025 and December 31, 2024, the Company’s equity method investments included investments in partnerships with a carrying value of approximately $1.4 billion. Refer to Note 7 for additional information on gains and losses on the Company’s investments including investments in the partnerships.
The cross-currency swap derivative contracts are classified as Level 2 in the fair value hierarchy as they are measured using the income approach with the relevant interest rates and current currency exchange rates and forward curves as inputs. Refer to Note 11 for additional information.
Fair Value of Other Financial Instruments
The carrying amounts and fair values of the Company’s other financial instruments were as follows ($ in millions):

| September 26, 2025 |  | December 31, 2024
| Carrying Amount |  | Fair Value |  | Carrying Amount |  | Fair Value
Debt obligations: |  |  |  |  |  |  |
Notes payable and current portion of long-term debt | $ | 23 |  |  | $ | 23 |  |  | $ | 505 |  |  | $ | 502 |
Long-term debt | 16,833 |  |  | 14,470 |  |  | 15,500 |  |  | 13,109 |

As of September 26, 2025 and December 31, 2024, short and long-term borrowings were categorized as Level 1. The fair value of long-term borrowings was based on quoted market prices. The difference between the fair value and the carrying amounts of long-term borrowings is attributable to changes in market interest rates and/or the Company’s credit ratings subsequent to the incurrence of the borrowing. The fair values of borrowings with original maturities of one year or less, as well as cash and cash equivalents, trade accounts receivable, net and trade accounts payable generally approximate their carrying amounts due to the short-term maturities of these instruments.
16

Table of Contents
NOTE 10. FINANCING
As of September 26, 2025, the Company was in compliance with all of its debt covenants. The components of the Company’s debt were as follows ($ in millions):

|  | Outstanding Amount
Description and Aggregate Principal Amount |  | September 26, 2025 |  | December 31, 2024
Euro-denominated commercial paper (€933 million and €931 million, respectively)(a) |  | $ | 1,092 |  |  | $ | 965 |
3.35% senior unsecured notes due 9/15/2025 ($500 million) (the “2025 U.S. Notes”)(b) |  | — |  |  | 500 |
0.2% senior unsecured notes due 3/18/2026 (€1.3 billion) (the “2026 Biopharma Euronotes”)(c) |  | 1,462 |  |  | 1,293 |
2.1% senior unsecured notes due 9/30/2026 (€800 million) (the “2026 Euronotes”)(b) |  | 936 |  |  | 828 |
0.3% senior unsecured notes due 5/11/2027 (¥30.8 billion) (the “2027 Yen Notes”)(d) |  | 206 |  |  | 195 |
1.2% senior unsecured notes due 6/30/2027 (€600 million) (the “2027 Euronotes”)(e) |  | 701 |  |  | 620 |
0.45% senior unsecured notes due 3/18/2028 (€1.3 billion) (the “2028 Biopharma Euronotes”)(c) |  | 1,460 |  |  | 1,291 |
1.125% senior unsecured bonds due 12/08/2028 (CHF 210 million) (the “2028 CHF Bonds”)(f) |  | 265 |  |  | 233 |
2.6% senior unsecured notes due 11/15/2029 ($800 million) (the “2029 Biopharma Notes”)(c) |  | 798 |  |  | 797 |
2.5% senior unsecured notes due 3/30/2030 (€800 million) (the “2030 Euronotes”)(b) |  | 936 |  |  | 829 |
0.75% senior unsecured notes due 9/18/2031 (€1.8 billion) (the “2031 Biopharma Euronotes”)(c) |  | 2,041 |  |  | 1,805 |
0.65% senior unsecured notes due 5/11/2032 (¥53.2 billion) (the “2032 Yen Notes”)(d) |  | 355 |  |  | 337 |
1.35% senior unsecured notes due 9/18/2039 (€1.3 billion) (the “2039 Biopharma Euronotes”)(c) |  | 1,450 |  |  | 1,282 |
3.25% senior unsecured notes due 11/15/2039 ($900 million) (the “2039 Biopharma Notes”)(c) |  | 892 |  |  | 892 |
4.375% senior unsecured notes due 9/15/2045 ($500 million) (the “2045 U.S. Notes”)(b) |  | 500 |  |  | 499 |
1.8% senior unsecured notes due 9/18/2049 (€750 million) (the “2049 Biopharma Euronotes”)(c) |  | 870 |  |  | 769 |
3.4% senior unsecured notes due 11/15/2049 ($900 million) (the “2049 Biopharma Notes”)(c) |  | 891 |  |  | 890 |
2.6% senior unsecured notes due 10/01/2050 ($1.0 billion) (the “2050 U.S. Notes”)(b) |  | 982 |  |  | 982 |
2.8% senior unsecured notes due 12/10/2051 ($1.0 billion) (the “2051 U.S. Notes”)(b) |  | 985 |  |  | 985 |
Other |  | 34 |  |  | 13 |
Total debt |  | 16,856 |  |  | 16,005 |
Less: currently payable |  | (23) |  |  | (505) |
Long-term debt |  | $ | 16,833 |  |  | $ | 15,500 |

(a) Issued by Danaher Corporation or DH Europe Finance II S.a.r.l. (“Danaher International II”).
(b) Issued by Danaher Corporation.
(c) Issued by Danaher International II.
(d) Issued by DH Japan Finance S.a.r.l. (“Danaher Japan”).
(e) Issued by DH Europe Finance S.a.r.l. (“Danaher International”).
(f) Issued by DH Switzerland Finance S.a.r.l. (“Danaher Switzerland”).
Debt discounts, premiums and debt issuance costs totaled $88 million and $96 million as of September 26, 2025 and December 31, 2024, respectively, and have been netted against the aggregate principal amounts of the related debt in the components of debt table above. For additional details regarding the Company’s debt financing, refer to Note 13 of the Company’s financial statements as of and for the year ended December 31, 2024 included in the Company’s 2024 Annual Report.
The Company has historically satisfied short-term liquidity needs that are not met through operating cash flow and available cash primarily through issuances of commercial paper under its U.S. dollar and euro-denominated commercial paper programs. The Company’s $5.0 billion unsecured, multi-year revolving credit facility with a syndicate of banks that expires on August 11, 2028 (the “Credit Facility”) is available for direct borrowings and provides credit support for the commercial paper programs. For a description of the Credit Facility, refer to the Company’s 2024 Annual Report. As of September 26, 2025, the Company has classified approximately $2.6 billion of its borrowings outstanding under the euro-denominated commercial paper programs and the 2026 Biopharma Euronotes as long-term debt in the accompanying Consolidated Condensed Balance Sheet (even though such borrowings are scheduled to mature within one year of September 26, 2025) as the Company had the intent and ability, as supported by availability under the Credit Facility, to refinance these borrowings for at least one year from the balance sheet date.
17

Table of Contents
As of September 26, 2025, borrowings outstanding under the Company’s euro-denominated commercial paper program had a weighted average annual interest rate of 2.2% and a weighted average remaining maturity of approximately 27 days. There were no borrowings outstanding under the U.S. dollar-denominated commercial paper program as of September 26, 2025.
Long-Term Debt Repayments
On September 15, 2025, the Company repaid the $500 million aggregate principal amount of the 2025 U.S. Notes upon their maturity using available cash and proceeds from the issuance of commercial paper.
2025 Debt Issuances
On October 10, 2025, Danaher Switzerland, a wholly-owned finance subsidiary of the Company, completed an underwritten offering of Swiss franc-denominated bonds due 2027, 2029, 2033, 2037 and 2045 (collectively the “Swiss Bonds”). The following summarizes the key terms of the offering in aggregate:

|  |  | Aggregate Principal Amount (in millions) |  | Stated Annual Interest Rate |  |  |  | Maturity Date |  | Interest Payment Dates (in arrears)
2027 CHF Bonds |  |  | CHF 250 |  | 0.4773 | % |  |  |  | April 9, 2027 |  | April 9
2029 CHF Bonds |  |  | CHF 325 |  | 0.8875 | % |  |  |  | October 10, 2029 |  | October 10
2033 CHF Bonds |  |  | CHF 325 |  | 1.265 | % |  |  |  | October 10, 2033 |  | October 10
2037 CHF Bonds |  |  | CHF 225 |  | 1.6249 | % |  |  |  | October 9, 2037 |  | October 9
2045 CHF Bonds |  |  | CHF 125 |  | 1.94 | % |  |  |  | October 10, 2045 |  | October 10
Total Swiss Bonds |  |  | CHF 1,250 |  |  |  |  |  |  |  |

The Company received net proceeds from the issuance, after underwriting discounts and commissions and offering expenses, of approximately CHF 1.2 billion (approximately $1.6 billion based on currency exchange rates as of the date of the pricing of the Swiss Bonds). The proceeds from the issuance have been and will be used for general corporate purposes, which may include share repurchases, repayment of debt, acquisitions, capital expenditures or other investing activities.
Guarantors of Debt
Danaher Corporation has guaranteed long-term debt and commercial paper issued by certain of its wholly-owned finance subsidiaries: Danaher International, Danaher International II, Danaher Switzerland and Danaher Japan. All of the outstanding and future securities issued by each of these entities are or will be fully and unconditionally guaranteed by Danaher Corporation and these guarantees rank on parity with Danaher Corporation’s unsecured and unsubordinated indebtedness.
NOTE 11. HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS
The Company uses cross-currency swap derivative contracts to partially hedge its net investments in non-U.S. operations against adverse movements in exchange rates between the U.S. dollar and the Danish kroner, Japanese yen, euro and Swiss franc. These contracts are agreements to exchange fixed-rate payments in one currency for fixed-rate payments in another currency and effectively convert U.S. dollar-denominated bonds to obligations denominated in the hedged currency. These contracts also reduce the interest rate from the stated interest rates on the U.S. dollar-denominated debt to the interest rates of the swaps. The changes in the spot rate of these instruments are recorded in accumulated other comprehensive income (loss) (“OCI”) in stockholders’ equity, partially offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated OCI. The interest income or expense from these swaps are recorded in interest expense in the accompanying Consolidated Condensed Statements of Earnings consistent with the classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from October 2025 to December 2031.
The Company also uses cross-currency swap derivative contracts to hedge U.S. dollar-denominated long-term debt issuances in a foreign subsidiary whose functional currency is the euro against adverse movements in exchange rates. These contracts effectively convert these U.S. dollar-denominated bonds to obligations denominated in euro. The changes in the fair value of these instruments are recorded in accumulated OCI and are subsequently reclassified to net earnings to offset the remeasurement of the hedged debt that is also recorded in net earnings. The interest income or expense from these swaps are recorded in interest expense in the accompanying Consolidated Condensed Statements of Earnings consistent with the classification of interest expense attributable to the underlying debt. These instruments mature on dates ranging from November 2029 to November 2049.
The Company has also issued foreign currency denominated long-term debt as partial hedges of its net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro, Japanese yen
18

Table of Contents
and Swiss franc. These debt issuances are designated and qualify as nonderivative hedging instruments. Accordingly, the foreign currency translation of these debt instruments is recorded in accumulated OCI, offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated OCI. These instruments mature on dates ranging from September 2025 to May 2032.
The Company used interest rate swap agreements to hedge the variability in cash flows due to changes in benchmark interest rates related to a portion of the debt the Company issued. These contracts effectively fixed the interest rate for a portion of the Company’s debt equal to the notional amount of the swaps to the rate specified in the interest rate swap agreements and were settled in November 2019 and December 2021. The changes in the fair value of these instruments were recorded in accumulated OCI prior to the issuance of the debt and are subsequently being reclassified to interest expense over the life of the related debt.
The following table summarizes the notional values as of September 26, 2025 and September 27, 2024 and pretax impact of changes in the fair values of instruments designated as net investment hedges and cash flow hedges in accumulated OCI for the three and nine-month periods ended September 26, 2025 and September 27, 2024 ($ in millions):

| Original Notional Amount |  | Notional Amount Outstanding |  | Gain (Loss) Recognized in OCI |  | Amounts Reclassified from OCI
For the Three-Month Period Ended September 26, 2025: |  |  |  |  |  |  |
Net investment hedges: |  |  |  |  |  |  |
Cross-currency contracts | $ | 3,875 |  |  | $ | 2,500 |  |  | $ | 22 |  |  | $ | — |
Foreign currency denominated debt | 4,490 |  |  | 4,490 |  |  | 21 |  |  | — |
Cash flow hedges: |  |  |  |  |  |  |
Cross-currency contracts | 4,000 |  |  | 2,600 |  |  | 49 |  |  | (1) |
Interest rate swaps | 1,600 |  |  | — |  |  | — |  |  | 1 |
Total | $ | 13,965 |  |  | $ | 9,590 |  |  | $ | 92 |  |  | $ | — |
For the Three-Month Period Ended September 27, 2024: |  |  |  |  |  |  |
Net investment hedges: |  |  |  |  |  |  |
Cross-currency contracts | $ | 3,875 |  |  | $ | 3,000 |  |  | $ | (97) |  |  | $ | — |
Foreign currency denominated debt | 3,294 |  |  | 3,294 |  |  | (185) |  |  | — |
Cash flow hedges: |  |  |  |  |  |  |
Cross-currency contracts | 4,000 |  |  | 3,300 |  |  | (77) |  |  | 140 |
Interest rate swaps | 1,600 |  |  | — |  |  | — |  |  | — |
Total | $ | 12,769 |  |  | $ | 9,594 |  |  | $ | (359) |  |  | $ | 140 |
For the Nine-Month Period Ended September 26, 2025: |  |  |  |  |  |  |
Net investment hedges: |  |  |  |  |  |  |
Cross-currency contracts | $ | 3,875 |  |  | $ | 2,500 |  |  | $ | (234) |  |  | $ | — |
Foreign currency denominated debt | 4,490 |  |  | 4,490 |  |  | (405) |  |  | — |
Cash flow hedges: |  |  |  |  |  |  |
Cross-currency contracts | 4,000 |  |  | 2,600 |  |  | (112) |  |  | 328 |
Interest rate swaps | 1,600 |  |  | — |  |  | — |  |  | 2 |
Total | $ | 13,965 |  |  | $ | 9,590 |  |  | $ | (751) |  |  | $ | 330 |
For the Nine-Month Period Ended September 27, 2024: |  |  |  |  |  |  |
Net investment hedges: |  |  |  |  |  |  |
Cross-currency contracts | $ | 3,875 |  |  | $ | 3,000 |  |  | $ | 10 |  |  | $ | — |
Foreign currency denominated debt | 3,294 |  |  | 3,294 |  |  | (3) |  |  | — |
Cash flow hedges: |  |  |  |  |  |  |
Cross-currency contracts | 4,000 |  |  | 3,300 |  |  | 1 |  |  | 41 |
Interest rate swaps | 1,600 |  |  | — |  |  | — |  |  | 2 |
Total | $ | 12,769 |  |  | $ | 9,594 |  |  | $ | 8 |  |  | $ | 43 |

19

Table of Contents
Gains or losses related to the net investment hedges are classified as foreign currency translation adjustments in the schedule of changes in OCI in Note 13, as these items are attributable to the Company’s hedges of its net investment in foreign operations. Gains or losses related to the cash flow hedges are classified as cash flow hedge adjustments in the schedule of changes in OCI in Note 13. The amount reclassified from OCI for the cross-currency swap derivative contracts that are cash flow hedges of the Company’s U.S. dollar-denominated debt was equal to the remeasurement amount recorded in the three and nine-month periods on the hedged debt.
The Company did not reclassify any other deferred gains or losses related to net investment hedges or cash flow hedges from accumulated OCI to earnings during the three and nine-month periods ended September 26, 2025 and September 27, 2024. In addition, the Company did not have any ineffectiveness related to net investment hedges or cash flow hedges during the three and nine-month periods ended September 26, 2025 and September 27, 2024. Should any ineffectiveness arise, any ineffective portions of the hedges would be reclassified from accumulated OCI into earnings during the period of change. The cash inflows and outflows associated with the Company’s derivative contracts designated as net investment hedges are classified in all other investing activities in the accompanying Consolidated Condensed Statements of Cash Flows. The cash inflows and outflows associated with the Company’s derivative contracts designated as cash flow hedges are classified in cash flows from operating activities in the accompanying Consolidated Condensed Statements of Cash Flows.
The Company’s derivative instruments, as well as its nonderivative debt instruments designated and qualifying as net investment hedges, were classified in the Company’s Consolidated Condensed Balance Sheets as follows ($ in millions):

| September 26, 2025 |  | December 31, 2024
Derivative assets: |  |  |
Other long-term assets | $ | 129 |  |  | $ | 415 |
Derivative liabilities: |  |  |
Accrued expenses and other liabilities | 44 |  |  | — |
Nonderivative hedging instruments: |  |  |
Long-term debt | 4,490 |  |  | 3,042 |

Amounts related to the Company’s derivatives expected to be reclassified from accumulated OCI to net earnings during the next 12 months, if interest rates and foreign exchange rates remain unchanged, were not significant.
NOTE 12. COMMITMENTS AND CONTINGENCIES
On July 17, 2023, a putative securities class action was filed in the United States District Court for the District of Columbia, captioned Hawkins v. Danaher Corporation et al., Case No. 1:23-cv-02055 (“Hawkins Action”). The complaint was amended on December 29, 2023 and names the Company and certain of its current or former officers. The complaint purports to assert claims under Section 10(b) of the Securities Exchange Act of 1934, as amended (the “1934 Act”), SEC Rule 10b-5, and Section 20(a) of the 1934 Act, on behalf of persons and entities who acquired our securities between January 27, 2022 and October 23, 2023 (the “Class Period”). Plaintiffs allege that, during the Class Period, defendants made material misrepresentations or omissions regarding, among other things, the Company’s anticipated revenues for its bioprocessing business that artificially inflated the Company’s stock price. Plaintiffs seek, among other things, damages in an unspecified amount, as well as fees and costs. The Company moved to dismiss the amended complaint on February 27, 2024, and on August 4, 2025, the court granted in part and denied in part the Company’s motion to dismiss.
Since January 2024, putative shareholder derivative cases have been filed in the United States District Court for the District of Delaware. Those cases have been consolidated and are captioned In re Danaher Corporation Derivative Litigation, No. 1:24-cv-00091-GBW (the “Derivative Action”). The Derivative Action names the Company as a nominal defendant and purports to bring claims on behalf of the Company against certain of the Company’s current and former directors and officers for alleged violations of the federal securities laws and breaches of their fiduciary duties, among other claims, in relation to substantially the same factual allegations as those made in the Hawkins Action. These actions seek to recover unspecified damages and other relief on the Company’s behalf. Proceedings in the Derivative Action have been stayed during the pendency of the Hawkins Action.
The outcomes of these legal proceedings remain uncertain and the Company is unable to reasonably estimate the possible loss or range of loss, if any.
For further discussion of the Company’s litigation and contingencies, refer to Note 17 of the Company’s financial statements as of and for the year ended December 31, 2024 included in the Company’s 2024 Annual Report.
20

Table of Contents
NOTE 13. STOCKHOLDERS' EQUITY AND STOCK-BASED COMPENSATION
Stockholders’ Equity
The Company’s Board of Directors has approved the following programs to repurchase shares of the Company’s common stock:

Name of program |  | Date of Board of Director approval |  | Number of shares of Company common stock approved for repurchase |  | Number of shares remaining available for repurchase as of September 26, 2025
2013 Repurchase Program |  | July 16, 2013 |  | 20,000,000 |  |  | — |
2024 Repurchase Program |  | July 22, 2024 |  | 20,000,000 |  |  | 2,000,000 |
2025 Repurchase Program |  | September 9, 2025 |  | 35,000,000 |  |  | 35,000,000 |

In each case, the approved program authorized or authorizes the repurchase of up to the specified number of shares of the Company’s common stock from time to time on the open market or in privately negotiated transactions. None of the repurchase programs were or are subject to an expiration date, and the timing and amount of any shares repurchased in the future will be determined by members of the Company’s management based on its evaluation of market conditions and other factors. Any repurchase program with remaining availability may be suspended or discontinued at any time. Repurchased shares are and will be available for use in connection with the Company’s equity compensation plans (or any successor plans) and for other corporate purposes.
During the three and nine-month periods ended September 27, 2024, the Company repurchased approximately 2.6 million and 20.0 million shares, respectively, of the Company’s common stock for $646 million and approximately $5.2 billion, respectively, inclusive of excise taxes as part of the 2013 Repurchase Program. Included within the shares repurchased under the 2013 Repurchase Program in the three and nine-month periods ended September 27, 2024 is the repurchase of $173 million of shares from the Danaher Corporation & Subsidiaries Pension Plan, a related party, at fair market value at the time of the purchase.
During the nine-month period ended September 26, 2025, the Company paid $56 million in excise taxes related to the 2024 share repurchases. Cash paid for excise taxes on share repurchases is included in all other financing activities in the accompanying Consolidated Condensed Statement of Cash Flows.
During the three and nine-month periods ended September 26, 2025, the Company repurchased 10.0 million and approximately 14.5 million shares, respectively, of the Company’s common stock for approximately $2.0 billion and $3.1 billion, respectively, (which includes $20 million and $24 million, respectively, of excise taxes which will be paid in 2026) as part of the 2024 Repurchase Program.
The following table summarizes the Company’s share activity (shares in millions):

| Three-Month Period Ended |  | Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Common stock - shares issued: |  |  |  |  |  |  |
Balance, beginning of period | 885.9 |  |  | 883.2 |  |  | 884.3 |  |  | 880.5 |
Common stock-based compensation awards | 0.4 |  |  | 0.7 |  |  | 2.0 |  |  | 3.4 |
Balance, end of period | 886.3 |  |  | 883.9 |  |  | 886.3 |  |  | 883.9 |

Stock-Based Compensation
For a full description of the Company’s stock-based compensation programs, refer to Note 18 of the Company’s financial statements as of and for the year ended December 31, 2024 included in the Company’s 2024 Annual Report. As of September 26, 2025, approximately 43 million shares of the Company’s common stock were reserved for issuance under the 2007 Omnibus Incentive Plan.
21

Table of Contents
The following summarizes the components of the Company’s stock-based compensation expense ($ in millions):

| Three-Month Period Ended |  | Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
RSUs/PSUs: |  |  |  |  |  |  |
Pretax compensation expense | $ | 49 |  |  | $ | 49 |  |  | $ | 137 |  |  | $ | 127 |
Income tax benefit | (10) |  |  | (11) |  |  | (28) |  |  | (27) |
RSU/PSU expense, net of income taxes | 39 |  |  | 38 |  |  | 109 |  |  | 100 |
Stock options: |  |  |  |  |  |  |
Pretax compensation expense | 34 |  |  | 35 |  |  | 98 |  |  | 104 |
Income tax benefit | (7) |  |  | (7) |  |  | (20) |  |  | (21) |
Stock option expense, net of income taxes | 27 |  |  | 28 |  |  | 78 |  |  | 83 |
Total stock-based compensation: |  |  |  |  |  |  |
Pretax compensation expense | 83 |  |  | 84 |  |  | 235 |  |  | 231 |
Income tax benefit | (17) |  |  | (18) |  |  | (48) |  |  | (48) |
Total stock-based compensation expense, net of income taxes | $ | 66 |  |  | $ | 66 |  |  | $ | 187 |  |  | $ | 183 |

Stock-based compensation has been recognized as a component of SG&A expenses in the accompanying Consolidated Condensed Statements of Earnings. As of September 26, 2025, $190 million of total unrecognized compensation cost related to RSUs/PSUs is expected to be recognized over a weighted average period of approximately two years. As of September 26, 2025, $167 million of total unrecognized compensation cost related to stock options is expected to be recognized over a weighted average period of approximately two years. Future compensation amounts will be adjusted for any changes in estimated forfeitures.
22

Table of Contents
Accumulated Other Comprehensive Income
Accumulated OCI refers to certain gains and losses that under U.S. GAAP are included in comprehensive income (loss) but are excluded from net earnings as these amounts are initially recorded as an adjustment to stockholders’ equity. Foreign currency translation adjustments generally relate to indefinite investments in non-U.S. subsidiaries, as well as the impact from the Company’s hedges of its net investment in foreign operations, including the Company’s cross-currency swap derivatives, net of any income tax impacts.
The changes in accumulated OCI by component are summarized below ($ in millions).

| Foreign Currency Translation Adjustments |  | Pension and Postretirement Plan Benefit Adjustments |  |  |  | Cash Flow Hedge Adjustments |  | Accumulated Comprehensive Income (Loss)
For the Three-Month Period Ended September 26, 2025: |  |  |  |  |  |  |  |  |
Balance, June 27, 2025 | $ | (427) |  |  | $ | (297) |  |  |  |  | $ | 155 |  |  | $ | (569) |
OCI before reclassifications: |  |  |  |  |  |  |  |  |
Increase (decrease) | (65) |  |  | — |  |  |  |  | 49 |  |  | (16) |
Income tax impact | (6) |  |  | — |  |  |  |  | — |  |  | (6) |
OCI before reclassifications, net of income taxes | (71) |  |  | — |  |  |  |  | 49 |  |  | (22) |
Reclassification adjustments: |  |  |  |  |  |  |  |  |
Increase (decrease) | — |  |  | 2 |  | (a) |  |  | — |  | (b) | 2 |
Income tax impact | — |  |  | — |  |  |  |  | (1) |  |  | (1) |
Reclassification adjustments, net of income taxes | — |  |  | 2 |  |  |  |  | (1) |  |  | 1 |
Net OCI, net of income taxes | (71) |  |  | 2 |  |  |  |  | 48 |  |  | (21) |
Balance, September 26, 2025 | $ | (498) |  |  | $ | (295) |  |  |  |  | $ | 203 |  |  | $ | (590) |
For the Three-Month Period Ended September 27, 2024: |  |  |  |  |  |  |  |  |
Balance, June 28, 2024 | $ | (2,273) |  |  | $ | (397) |  |  |  |  | $ | 79 |  |  | $ | (2,591) |
OCI before reclassifications: |  |  |  |  |  |  |  |  |
Increase (decrease) | 1,193 |  |  | — |  |  |  |  | (77) |  |  | 1,116 |
Income tax impact | 23 |  |  | — |  |  |  |  | — |  |  | 23 |
OCI before reclassifications, net of income taxes | 1,216 |  |  | — |  |  |  |  | (77) |  |  | 1,139 |
Reclassification adjustments: |  |  |  |  |  |  |  |  |
Increase (decrease) | — |  |  | 3 |  | (a) |  |  | 140 |  | (b) | 143 |
Income tax impact | — |  |  | (1) |  |  |  |  | — |  |  | (1) |
Reclassification adjustments, net of income taxes | — |  |  | 2 |  |  |  |  | 140 |  |  | 142 |
Net OCI, net of income taxes | 1,216 |  |  | 2 |  |  |  |  | 63 |  |  | 1,281 |
Balance, September 27, 2024 | $ | (1,057) |  |  | $ | (395) |  |  |  |  | $ | 142 |  |  | $ | (1,310) |

23

Table of Contents

| Foreign Currency Translation Adjustments |  | Pension and Postretirement Plan Benefit Adjustments |  |  |  | Cash Flow Hedge Adjustments |  | Accumulated Comprehensive Income (Loss)
For the Nine-Month Period Ended September 26, 2025: |  |  |  |  |  |  |  |  |
Balance, December 31, 2024 | $ | (2,904) |  |  | $ | (300) |  |  |  |  | $ | (14) |  |  | $ | (3,218) |
OCI before reclassifications: |  |  |  |  |  |  |  |  |
Increase (decrease) | 2,350 |  |  | — |  |  |  |  | (112) |  |  | 2,238 |
Income tax impact | 56 |  |  | — |  |  |  |  | — |  |  | 56 |
OCI before reclassifications, net of income taxes | 2,406 |  |  | — |  |  |  |  | (112) |  |  | 2,294 |
Reclassification adjustments: |  |  |  |  |  |  |  |  |
Increase (decrease) | — |  |  | 6 |  | (a) |  |  | 330 |  | (b) | 336 |
Income tax impact | — |  |  | (1) |  |  |  |  | (1) |  |  | (2) |
Reclassification adjustments, net of income taxes | — |  |  | 5 |  |  |  |  | 329 |  |  | 334 |
Net OCI, net of income taxes | 2,406 |  |  | 5 |  |  |  |  | 217 |  |  | 2,628 |
Balance, September 26, 2025 | $ | (498) |  |  | $ | (295) |  |  |  |  | $ | 203 |  |  | $ | (590) |
For the Nine-Month Period Ended September 27, 2024: |  |  |  |  |  |  |  |  |
Balance, December 31, 2023 | $ | (1,446) |  |  | $ | (401) |  |  |  |  | $ | 99 |  |  | $ | (1,748) |
OCI before reclassifications: |  |  |  |  |  |  |  |  |
Increase (decrease) | 391 |  |  | — |  |  |  |  | 1 |  |  | 392 |
Income tax impact | (2) |  |  | — |  |  |  |  | — |  |  | (2) |
OCI before reclassifications, net of income taxes | 389 |  |  | — |  |  |  |  | 1 |  |  | 390 |
Reclassification adjustments: |  |  |  |  |  |  |  |  |
Increase (decrease) | — |  |  | 8 |  | (a) |  |  | 43 |  | (b) | 51 |
Income tax impact | — |  |  | (2) |  |  |  |  | (1) |  |  | (3) |
Reclassification adjustments, net of income taxes | — |  |  | 6 |  |  |  |  | 42 |  |  | 48 |
Net OCI, net of income taxes | 389 |  |  | 6 |  |  |  |  | 43 |  |  | 438 |
Balance, September 27, 2024 | $ | (1,057) |  |  | $ | (395) |  |  |  |  | $ | 142 |  |  | $ | (1,310) |

(a) This accumulated other comprehensive income (loss) component is included in the computation of net periodic benefit cost (refer to Note 7 for additional details).
(b) Reflects reclassification to earnings related to cash flow hedges of certain long-term debt (refer to Note 11 for additional details).
24

Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is designed to provide material information relevant to an assessment of Danaher Corporation’s (“Danaher,” the “Company,” “we,” “us” or “our”) financial condition and results of operations, including an evaluation of the amounts and certainty of cash flows from operations and from outside sources. The MD&A is designed to focus specifically on material events and uncertainties known to management that are reasonably likely to cause reported financial information not to be necessarily indicative of future operating results or of future financial condition. This includes descriptions and amounts of matters that have had a material impact on reported operations, as well as matters that are reasonably likely based on management’s assessment to have a material impact on future operations. The Company’s MD&A is divided into five sections:
•Information Relating to Forward-Looking Statements
•Overview
•Results of Operations
•Liquidity and Capital Resources
•Critical Accounting Estimates
You should read this discussion along with the Company’s MD&A and audited financial statements and Notes thereto as of and for the year ended December 31, 2024, included in the Company’s 2024 Annual Report and the Company’s Consolidated Condensed Financial Statements and related Notes as of and for the three and nine-month periods ended September 26, 2025 included in this Quarterly Report on Form 10-Q (“Report”).
INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS
Certain statements included or incorporated by reference in this Report, in other documents we file with or furnish to the Securities and Exchange Commission, in our press releases, webcasts, conference calls, presentations, materials delivered to shareholders and other communications, are “forward-looking statements” within the meaning of the U.S. federal securities laws. All statements other than historical factual information are forward-looking statements, including without limitation statements regarding: projections of tariff or other trade-related impacts, expected impacts of the U.S. government shutdown, revenue, expenses, profit, profit margins, asset values, pricing, tax rates, tax provisions, cash flows, pension and benefit obligations and funding requirements, our liquidity position or other projected financial measures; management’s plans and strategies for future operations, including statements relating to anticipated operating performance, customer demand, cost reductions, restructuring activities, new product and service developments, competitive strengths or market position, acquisitions and the integration thereof, divestitures, spin-offs, split-offs, initial public offerings, other securities offerings or other distributions, strategic opportunities, stock repurchases, dividends, executive compensation and potential executive stock sales or purchases; growth, declines and other trends in markets we sell into; future, new or modified laws, regulations, accounting pronouncements or public policy changes; regulatory approvals and the timing and conditionality thereof; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; future currency exchange rates and fluctuations in those rates; the potential or anticipated direct or indirect impact of public health crises, climate change, military or geopolitical conflicts or other man-made or natural disasters on our business, results of operations and/or financial condition; general economic and capital markets conditions; the anticipated timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that Danaher intends or believes will or may occur in the future. Terminology such as “believe,” “anticipate,” “assume,” “continue,” “should,” “could,” “intend,” “will,” “plan,” “aim,” “expect,” “estimate,” “project,” “target,” “can,” “may,” “possible,” “potential,” “upcoming,” “forecast” and “positioned” and similar references to future periods are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words.
Forward-looking statements are based on assumptions and assessments made by our management in light of their experience and perceptions of historical trends, current conditions, expected future developments and other factors. Forward-looking statements are not guarantees of future performance and actual results may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. Important factors, risks and uncertainties that in the
25

Table of Contents
future could cause actual results to differ materially from those envisaged in the forward-looking statements, and that in some cases have affected us in the past, include the following:
Business and Strategic Risks
•Conditions in the global economy, the particular markets we serve and the financial markets (including economic impacts from the U.S. government shutdown that began in October 2025) can adversely affect our business and financial statements.
•We face intense competition and if we are unable to compete effectively, we may experience decreased demand and decreased market share. Even if we compete effectively, we may be required to reduce the prices we charge.
•Our growth depends on the timely development and commercialization, and customer acceptance, of new and enhanced products and services based on technological innovation. Our growth also suffers when the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality.
•The healthcare industry and related industries that we serve are undergoing significant changes in an effort to reduce (and increase the predictability of) costs, which can adversely affect our business and financial statements.
•Economic, political, geopolitical, legal, compliance, social and business factors (including the impact of military conflicts), both in the U.S. and outside the U.S., can negatively affect our business and financial statements. For example, elections can result in significant political shifts and/or disruptions, and the 2025 change in the U.S. administration as well as recent Supreme Court decisions have resulted in policy, regulatory and economic changes, challenges and uncertainty, including with respect to tariffs and healthcare-related topics. Delays in National Institutes of Health (“NIH”) funding related to the U.S. government shutdown that commenced in October 2025 may also negatively affect our business and financial statements.
•Uncertainties with respect to the development, deployment and use of artificial intelligence in our business and products may result in harm to our business and reputation.
•Global heath crises, pandemics, epidemics or other outbreaks can adversely impact certain elements of our business and financial statements.
•Business partners and other third-parties we rely on for development, supply and/or marketing of certain products, potential products and technologies could fail to perform sufficiently.
Acquisitions, Divestitures and Investment Risks
•The inability to consummate acquisitions at our historical rate and appropriate prices, realize the economic benefits of consummated acquisitions or to make appropriate investments that support our long-term strategy, can negatively impact our business. Our acquisition of businesses, investments, joint ventures and other strategic relationships can also negatively impact our business and financial statements and our indemnification rights may not fully protect us from liabilities related thereto.
•Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we or our predecessors have previously disposed could adversely affect our business and financial statements. For example, we could incur significant liability if any of the split-off or spin-off transactions we have previously consummated are determined to be a taxable transaction or otherwise pursuant to our indemnification obligations with respect to such transactions.
Operational Risks
•Significant disruptions in, or breaches in security of, our information technology (“IT”) systems or data; data privacy violations; other losses or disruptions to facilities, supply chains, distribution systems or IT systems due to catastrophe; and labor disputes can all adversely affect our business and financial statements.
•Defects, manufacturing problems and unanticipated use or inadequate disclosure with respect to our products or services, or allegations thereof, can adversely affect our business and financial statements.
•Climate change, legal or regulatory measures to address climate change and other sustainability topics and any inability to address regulatory requirements or stakeholder expectations with respect to climate change and other sustainability topics, may negatively affect our business and financial statements.
•Our financial results are subject to fluctuations in the cost and availability of the supplies we use in, and the labor we need for, our operations, as well as adverse changes with respect to key distributors and channel partners.
26

Table of Contents
•Our success depends on our ability to recruit, retain and motivate talented employees.
•Our restructuring actions can have long-term adverse effects on our business and financial statements.
Intellectual Property Risks
•Any inability to adequately protect or avoid third-party infringement of our intellectual property, and third-party claims we are infringing intellectual property rights, can adversely affect our business and financial statements.
•The U.S. government has certain rights with respect to incremental production capacity attributable to, and/or the intellectual property we have developed using, government financing. In addition, in times of national emergency the U.S. government could also control our allocation of manufacturing capacity.
Financial and Tax Risks
•From time to time our outstanding debt has increased significantly as a result of acquisitions and other factors, and we may incur additional debt. Such indebtedness may limit our operations and use of cash flow and negatively impact our credit ratings; and failure to comply with our indebtedness-related covenants could adversely affect our business and financial statements.
•Our business and financial statements can be adversely affected by foreign currency exchange rates, changes in our tax rates (including as a result of changes in tax laws) or income tax liabilities/assessments, the outcome of tax audits, recognition of impairment charges for our goodwill or other intangible assets and fluctuations in the cost and availability of commodities.
Legal, Regulatory, Compliance and Reputational Risks
•Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition can have an adverse effect on our business and financial statements.
•Our businesses are subject to extensive regulation (including those applicable to the healthcare industry). Failure to comply with those regulations (including by our employees, agents or business partners) or significant developments or changes in U.S. or non-U.S. laws or policies can adversely affect our business and financial statements.
•We are subject to, or otherwise responsible for, a variety of litigation and other legal and regulatory proceedings in the course of our business that can adversely affect our business and financial statements.
•With respect to the regulated medical devices we offer, product introductions or modifications can require regulatory clearance or authorizations and we can be required to recall or cease marketing such products; off-label marketing can result in penalties; and clinical trials can have results that are unexpected or are perceived unfavorably by the market, all of which can adversely affect our business and financial statements.
•Our operations, products and services also expose us to the risk of environmental, health and safety liabilities, costs and violations that can adversely affect our business and financial statements.
•Our By-law exclusive forum provisions could limit our stockholders’ ability to choose their preferred judicial forum for disputes.
See “Part I—Item 1A. Risk Factors” of the Company’s 2024 Annual Report and Part II-Item 1A of this report for further discussion regarding reasons that actual results may differ materially from the results, developments and business decisions contemplated by our forward-looking statements. Forward-looking statements speak only as of the date of the report, document, press release, webcast, call, presentation, materials or other communication in which they are made. Except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
OVERVIEW
General
As a result of the Company’s geographic and industry diversity, the Company faces a variety of opportunities and challenges, including rapid technological development (particularly with respect to computing, automation, artificial intelligence, mobile connectivity and digitization) in most of the Company’s served markets, the expansion and evolution of opportunities in high-growth markets, trends and costs associated with a global labor force, consolidation of the Company’s competitors, increasing regulation and a rapidly evolving global trade environment. The Company operates in a highly competitive business environment in most markets, and the Company’s long-term growth and profitability will depend in particular on its ability to expand its business in high-growth geographies and high-growth market segments, identify, consummate and integrate appropriate acquisitions and identify and consummate appropriate investments and
27

Table of Contents
strategic partnerships, develop innovative and differentiated new products and services with higher gross profit margins, expand and improve the effectiveness of the Company’s sales force, continue to reduce costs and improve operating efficiency and quality and effectively address the demands of an increasingly regulated global environment and the evolving trade environment. The Company is making significant investments, organically and through acquisitions and investments, to address the rapid pace of technological change in its served markets and to position its manufacturing, research and development and customer-facing resources to be responsive to the Company’s customers throughout the world and improve the efficiency of the Company’s operations.
Business Performance and Outlook
During the third quarter of 2025, the Company’s overall revenues and core sales increased 4.5% and 3.0%, respectively, compared to the comparable period of 2024. For the nine-month period ended September 26, 2025, overall revenues and core sales increased 2.5% and 1.5%, respectively, compared to the comparable prior year period. In both periods, the increase in core sales is due to higher core sales in the Biotechnology and Diagnostics segments that were partially offset by lower core sales in the Life Sciences segment. In the three and nine-month periods ended September 26, 2025, the impact of foreign currency increased reported sales by 1.5% and 1.0%, respectively. Price increases contributed 0.5% to sales growth on a year-over-year basis during both the three and nine-month periods ended September 26, 2025 and are reflected as a component of core sales above. For the definitions of “core sales” and “acquisitions” refer to “—Results of Operations” below.
Geographically, the Company’s sales in the three-month period ended September 26, 2025 in developed markets increased year-over-year by 5% and core sales in developed markets were up mid-single digits, primarily due to mid-single digit core sales increases in North America. The increase in core sales in developed markets was primarily driven by increases in the Diagnostics and Biotechnology segments, partially offset by decreased year-over-year core sales in the Life Sciences segment. For the same period, sales in high-growth markets increased year-over-year by 2% and core sales were up low-single digits as a mid-single digit decline in core revenue in China was more than offset by increased core sales in other regions. In the high-growth markets, the Life Sciences and Biotechnology segments’ increase in demand was partially offset by core sales declines in the Diagnostics segment. High-growth markets represented approximately 29% of the Company’s total sales in the third quarter of 2025. For additional information regarding the Company’s sales by geographical region during the three and nine-month periods ended September 26, 2025 and September 27, 2024, refer to Note 4 to the accompanying Consolidated Condensed Financial Statements.
The Company’s net earnings for the three and nine-month periods ended September 26, 2025 totaled $908 million and approximately $2.4 billion, or $1.27 and $3.37 per diluted common share, respectively, compared to $818 million and approximately $2.8 billion, or $1.12 and $3.80 per diluted common share, respectively, for the three and nine-month periods ended September 27, 2024. Impairment charges of $548 million ($409 million after-tax or $0.57 per diluted common share) recorded in the nine-month period ended September 26, 2025, net of impairment charges of $222 million ($169 million after-tax or $0.23 per diluted common share) recorded in the nine-month period ended September 27, 2024, and investment losses in the nine-month period ended September 26, 2025, net of investment gains in the nine-month period ended September 27, 2024, were the primary reasons for the year-over-year decline in net earnings and diluted net earnings per common share for the nine-month period ended September 26, 2025.
Currency exchange rates increased reported sales by approximately 1.5% and 1.0% for the three and nine-month periods ended September 26, 2025, respectively, compared to the comparable periods of 2024, primarily due to the exchange rates of the U.S. dollar compared to the euro and other major currencies. In future periods, strengthening of the U.S. dollar against other major currencies compared to the exchange rates in effect as of September 26, 2025 would adversely impact the Company’s sales and results of operations on an overall basis, and weakening of the U.S. dollar against other major currencies compared to the exchange rates in effect as of September 26, 2025 would positively impact the Company’s sales and results of operations. In addition to the translational exchange rate risk to sales, the Company also faces transactional exchange rate risk from transactions with customers in countries outside the U.S. and from intercompany transactions between affiliates. Transactional exchange rate risk (and any resulting gains or losses) arises from the purchase and sale of goods and services in currencies other than the Company’s functional currency or the functional currency of its applicable subsidiary.
Danaher operates a diversified global supply chain and sources parts and materials globally. During 2025, the U.S. has implemented significant new tariffs on imports from a wide range of countries, which has also prompted retaliatory tariffs by a number of countries, including tariffs and export restrictions on certain manufacturing components imposed by China and tariffs pursuant to trade agreements the U.S. has entered into with certain countries. In addition, a number of new tariffs have been threatened and the U.S. and other countries continue to negotiate trade arrangements and tariff levels. In August 2025, the U.S. Court of Appeals for the Federal Circuit ruled against certain of the U.S. tariffs that have been implemented. The U.S. administration has appealed this ruling and the U.S. Supreme Court has agreed to hear the case, with oral arguments anticipated in November 2025.
28

Table of Contents
Based on the tariffs enacted and in effect as of October 19, 2025 (the “enacted tariffs”), the Company anticipates incurring incremental tariff costs for the full year 2025 of several hundred million dollars. These incremental costs from the enacted tariffs reflect their impact on the costs of parts and materials used by the Company to produce products, as well as costs the Company incurs on finished goods shipped to customers. The Company expects to, and has thus far, largely offset the operating profit impact of the enacted tariffs with manufacturing footprint changes, supply chain adjustments, surcharges and additional productivity and cost savings actions. To the extent the Company is unable to continue to offset the incremental cost from the enacted tariffs, the enacted tariffs negatively impact demand or the export restrictions negatively impact manufacturing, the Company’s revenue and profitability would be adversely impacted. If delayed tariffs come into effect or other additional tariffs are adopted, the Company would incur additional tariff costs that could be material and the Company’s revenue and profitability could be adversely impacted.
In addition to changes in trade policy, the new U.S. administration has implemented a number of other regulatory, policy and personnel changes, including the elimination, downsizing and reduced funding of certain government agencies and programs and the cancellation or delay of government contracts and research grants, each of which may be exacerbated by the U.S. government shutdown that began in October 2025. In addition, the administration has changed the composition of and guidance from advisory panels on healthcare practices.
The full impact of the matters noted above on the Company, our customers, end-users and business partners, the overall economy and capital markets remains uncertain. The Company currently expects academic and government demand to remain weaker with ongoing uncertainty around research funding and a cautious bioprocessing equipment spending environment. Refer to “Risk Factors” for additional information.
RESULTS OF OPERATIONS
Non-GAAP Measures
In this report, references to the non-GAAP measure of core sales (also referred to as core revenues or sales/revenues from existing businesses) refer to sales calculated according to U.S. GAAP, but excluding:
•sales from acquired businesses (as defined below); and
•the impact of currency translation.
References to sales or operating profit attributable to acquisitions or acquired businesses refer to sales or operating profit, as applicable, from acquired businesses recorded prior to the first anniversary of the acquisition less any sales and operating profit, during the applicable period, attributable to divested product lines not considered discontinued operations. The portion of revenue attributable to currency translation is calculated as the difference between:
•the period-to-period change in revenue (excluding sales from acquired businesses (as defined above)); and
•the period-to-period change in revenue (excluding sales from acquired businesses (as defined above)) after applying current period foreign exchange rates to the prior year period.
Core sales growth (decline) should be considered in addition to, and not as a replacement for or superior to, sales, and may not be comparable to similarly titled measures reported by other companies. Management believes that reporting this non-GAAP financial measure provides useful information to investors by helping identify underlying growth trends in Danaher’s business and facilitating comparisons of Danaher’s revenue performance with its performance in prior and future periods and to Danaher’s peers. Management also uses this non-GAAP financial measure to measure the Company’s operating and financial performance and uses core sales growth as one of the performance measures in the Company’s executive short-term cash incentive compensation program. The Company excludes the effect of currency translation from this measure because currency translation is not under management’s control, is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestiture-related items because the nature, size, timing and number of acquisitions and divestitures can vary dramatically from period-to-period and between the Company and its peers and can also obscure underlying business trends and make comparisons of long-term performance difficult.
Throughout this discussion, references to sales growth or decline refer to the impact of both price and unit sales and references to productivity improvements generally refer to improved cost-efficiencies resulting from the ongoing application of the Danaher Business System.
29

Table of Contents
Sales Growth and Core Sales Growth

| % Change Three-Month Period Ended September 26, 2025 vs. Comparable 2024 Period |  | % Change Nine-Month Period Ended September 26, 2025 vs. Comparable 2024 Period
Total sales growth (GAAP) | 4.5 | % |  | 2.5 | %
Impact of: |  |  |
Currency exchange rates | (1.5) | % |  | (1.0) | %
Core sales growth (non-GAAP) | 3.0 | % |  | 1.5 | %

Operating Profit Performance
Operating profit margins increased 260 basis points from 16.5% during the three-month period ended September 27, 2024 to 19.1% for the three-month period ended September 26, 2025.
Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were favorably impacted by:
•Third quarter 2024 impairment charge related to a trade name in the Life Sciences segment, net of impairment charges related to technology and other assets in the Biotechnology segment and a trade name in the Diagnostics segment in the third quarter of 2025. Refer to Note 8 to the accompanying Consolidated Condensed Financial Statements for additional information regarding the impairments - 220 basis points
•Higher 2025 core sales, net of the impact of changes in leverage from the Company’s operations and administrative cost structure and the impact of product mix - 45 basis points
Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were unfavorably impacted by:
•Incremental dilutive effect in 2025 of acquired businesses and the impact of a product line disposition which did not qualify as discontinued operations - 5 basis points
Operating profit margins decreased 180 basis points from 19.8% during the nine-month period ended September 27, 2024 to 18.0% for the nine-month period ended September 26, 2025.
Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were unfavorably impacted by:
•First nine months of 2025 impairment charges related to trade names in the Life Sciences and Diagnostics segments, and impairment charges related to technology, other intangible assets and a facility in the Biotechnology segment, net of an impairment charge related to a trade name in the Life Sciences segment in the first nine months of 2024 - 180 basis points
•Incremental dilutive effect in 2025 of acquired businesses and the impact of a product line disposition which did not qualify as discontinued operations - 20 basis points
Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were favorably impacted by:
•First nine months of 2024 acquisition-related fair value adjustment to inventory - 15 basis points
•Higher 2025 core sales and the impact of product mix, net of the impact of changes in leverage from the Company’s operations and administrative cost structure and the impact of currency exchange rates - 5 basis points
Business Segments
Sales by business segment for each of the periods indicated were as follows ($ in millions):

| Three-Month Period Ended |  | Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Biotechnology | $ | 1,798 |  |  | $ | 1,653 |  |  | $ | 5,260 |  |  | $ | 4,890 |
Life Sciences | 1,792 |  |  | 1,782 |  |  | 5,249 |  |  | 5,297 |
Diagnostics | 2,463 |  |  | 2,363 |  |  | 7,221 |  |  | 7,150 |
Total | $ | 6,053 |  |  | $ | 5,798 |  |  | $ | 17,730 |  |  | $ | 17,337 |

For information regarding the Company’s sales by geographical region, refer to Note 4 to the accompanying Consolidated Condensed Financial Statements.
30

Table of Contents
BIOTECHNOLOGY
The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Company’s solutions support a broad range of biotherapeutics including monoclonal antibodies, recombinant proteins, replacement therapies such as insulin and vaccines, as well as novel cell, gene, mRNA and other nucleic acid therapies.
Biotechnology Selected Financial Data

| Three-Month Period Ended |  | Nine-Month Period Ended
($ in millions) | September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Sales | $ | 1,798 |  |  | $ | 1,653 |  |  | $ | 5,260 |  |  | $ | 4,890 |
Operating profit | 352 |  |  | 390 |  |  | 1,324 |  |  | 1,177 |
Depreciation | 38 |  |  | 36 |  |  | 110 |  |  | 113 |
Amortization of intangible assets | 231 |  |  | 218 |  |  | 672 |  |  | 650 |
Operating profit as a % of sales | 19.6 | % |  | 23.6 | % |  | 25.2 | % |  | 24.1 | %
Depreciation as a % of sales | 2.1 | % |  | 2.2 | % |  | 2.1 | % |  | 2.3 | %
Amortization as a % of sales | 12.8 | % |  | 13.2 | % |  | 12.8 | % |  | 13.3 | %

Sales Growth and Core Sales Growth

| % Change Three-Month Period Ended September 26, 2025 vs. Comparable 2024 Period |  | % Change Nine-Month Period Ended September 26, 2025 vs. Comparable 2024 Period |  |
Total sales growth (GAAP) | 9.0 | % |  | 7.5 | % |  |
Impact of: |  |  |  |  |
Currency exchange rates | (2.5) | % |  | (1.0) | % |  |
Core sales growth (non-GAAP) | 6.5 | % |  | 6.5 | % |  |

Price increases in the segment contributed 2.5% and 2.0%, respectively, to sales growth on a year-over-year basis during the three and nine-month periods ended September 26, 2025 and are reflected as a component of core sales above.
Total segment sales increased 9.0% and 7.5% during the three and nine-month periods, respectively. The increase in segment sales in the three and nine-month periods was led by increased core sales and to a lesser extent by the impact of currency exchange rates. The year-over-year increase in total segment core sales in both periods was led by increased sales of consumables, partially offset by declines in equipment sales. Geographically, the increase in core sales was led by North America in the three-month period and North America and Western Europe in the nine-month period. Based on the current market conditions, the Company expects a cautious equipment spending environment through the remainder of the year.
The year-over-year increase in core sales in the segment was led by high-single digit increases in core sales in the bioprocessing business in both the three and nine-month periods and was primarily driven by improved consumables demand from large pharmaceutical customers, partially offset by lower year-over-year demand for equipment. Core sales in the discovery and medical business increased year-over-year as demand for medical and lab filtration consumables more than offset lower demand for protein research equipment in the life science research end-markets.
Operating Profit Performance
Operating profit margins decreased 400 basis points during the three-month period ended September 26, 2025 as compared to the comparable period of 2024.
Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were unfavorably impacted by:
•Third quarter 2025 impairment charge related to technology and other intangible assets - 475 basis points
Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were favorably impacted by:
•Higher third quarter 2025 core sales and the impact of product mix, net of the impact of changes in leverage from the Company’s operations and administrative cost structure and the impact of currency exchange rates - 75 basis points
31

Table of Contents
Operating profit margins increased 110 basis points during the nine-month period ended September 26, 2025 as compared to the comparable period of 2024.
Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were favorably impacted by:
•Higher 2025 core sales and the impact of product mix, net of the impact of currency exchange rates - 300 basis points
Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were unfavorably impacted by:
•First nine months of 2025 impairment charges related to technology, other intangible assets and a facility - 190 basis points
Amortization of intangible assets as a percentage of sales decreased during both the three and nine-month periods ended September 26, 2025 as compared to the comparable periods of 2024, primarily as a result of the increase in sales.
LIFE SCIENCES
The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including DNA and RNA, nucleic acid, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies, and test and manufacture new drugs, vaccines and gene editing technologies. Additionally, the segment provides products and consumables used to filter and remove contaminants from a variety of liquids and gases in many end-market applications.
As discussed in Note 8 to the accompanying Consolidated Condensed Financial Statements, during the third quarter of 2025, the Company reorganized and integrated certain businesses within its Life Sciences segment to better serve the Company’s customers in new market segments and to respond to current market conditions. The life sciences instruments business includes the flow cytometry and lab automation solutions business, the mass spectrometry business and the microscopy business. The life science consumables business includes the genomic medicines businesses and the protein consumables business.
Life Sciences Selected Financial Data

| Three-Month Period Ended |  | Nine-Month Period Ended
($ in millions) | September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Sales | $ | 1,792 |  |  | $ | 1,782 |  |  | $ | 5,249 |  |  | $ | 5,297 |
Operating profit | 222 |  |  | 35 |  |  | 184 |  |  | 503 |
Depreciation | 47 |  |  | 44 |  |  | 137 |  |  | 123 |
Amortization of intangible assets | 154 |  |  | 147 |  |  | 453 |  |  | 428 |
Operating profit as a % of sales | 12.4 | % |  | 2.0 | % |  | 3.5 | % |  | 9.5 | %
Depreciation as a % of sales | 2.6 | % |  | 2.5 | % |  | 2.6 | % |  | 2.3 | %
Amortization as a % of sales | 8.6 | % |  | 8.2 | % |  | 8.6 | % |  | 8.1 | %

Sales Growth (Decline) and Core Sales Decline

| % Change Three-Month Period Ended September 26, 2025 vs. Comparable 2024 Period |  | % Change Nine-Month Period Ended September 26, 2025 vs. Comparable 2024 Period
Total sales growth (decline) (GAAP) | 0.5 | % |  | (1.0) | %
Impact of: |  |  |
Acquisitions | — | % |  | (1.0) | %
Currency exchange rates | (1.5) | % |  | (0.5) | %
Core sales decline (non-GAAP) | (1.0) | % |  | (2.5) | %

Price increases in the segment contributed 1.0% and 0.5% to the change in sales on a year-over-year basis during the three and nine-month periods ended September 26, 2025, respectively, and are reflected as a component of core sales above.
32

Table of Contents
Total segment sales increased 0.5% and decreased 1.0% during the three and nine-month periods ended September 26, 2025, respectively. The sales increase during the three-month period was driven by currency exchange rates, partially offset by a decline in core sales. The sales decline during the nine-month period was primarily a result of decreased core sales, partially offset by the impact of acquisitions and to a lesser extent, the impact of currency exchange rates. The year-over-year decrease in total segment core sales in the three-month period ended September 26, 2025 was driven by a decline in consumables sales, partially offset by increased demand for equipment. In the nine-month period ended September 26, 2025, the year-over-year decrease in total segment core sales was driven by declines in both consumables and equipment sales. Lower funding levels at emerging biotechnology customers and in the academic and government end-markets reduced demand for the segment’s products in both periods. Geographically, the core sales decline in both periods was led by North America.
The year-over-year decrease in segment core sales in the three and nine-month periods was led by the life science consumables businesses, primarily in North America, driven by lower demand for the plasmids and mRNA product lines at two large customers and lower funding levels at emerging biotechnology and academic research customers. In the life science instruments businesses, core sales increased in the three-month period and decreased in the nine-month period, as declines in equipment demand in both periods was more than offset by increased demand for consumables and software in the three-month period. In both periods, core sales in the microscopy and mass spectrometry businesses decreased, while core sales at the flow cytometry and lab automation solutions business increased. During both periods, year-over-year core sales increased in the filtration business. In the three-month period, core sales in filtration increased in all major end-markets while in the nine-month period, increased demand in the microelectronic and aerospace end-markets more than offset decreased year-over-year demand in the energy-related end-market.
Operating Profit Performance
Operating profit margins increased 1,040 basis points during the three-month period ended September 26, 2025 as compared to the comparable period of 2024.
Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were favorably impacted by:
•Third quarter 2024 impairment charge related to a trade name - 1,245 basis points
Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were unfavorably impacted by:
•Lower third quarter 2025 core sales, the impact of product mix and the impact of changes in leverage from the segment’s operational and administrative cost structure, net of the impact of currency exchange rates - 205 basis points
Operating profit margins decreased 600 basis points during the nine-month period ended September 26, 2025 as compared to the comparable period of 2024.
Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were unfavorably impacted by:
•First nine months of 2025 impairment charge related to a trade name, net of an impairment charge related to a trade name in the first nine months of 2024 - 405 basis points
•Lower 2025 core sales, the impact of product mix and the impact of changes in leverage from the segment’s operational and administrative cost structure - 205 basis points
•The incremental dilutive effect in 2025 of acquired businesses - 35 basis points
Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were favorably impacted by:
•First nine months of 2024 acquisition-related fair value adjustment to inventory - 45 basis points
Depreciation and amortization of intangible assets increased as a percentage of sales during both the three and nine-month periods ended September 26, 2025, primarily due to the impact of acquisitions.
33

Table of Contents
DIAGNOSTICS
The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Diagnostics Selected Financial Data

| Three-Month Period Ended |  | Nine-Month Period Ended
($ in millions) | September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Sales | $ | 2,463 |  |  | $ | 2,363 |  |  | $ | 7,221 |  |  | $ | 7,150 |
Operating profit | 665 |  |  | 615 |  |  | 1,937 |  |  | 2,001 |
Depreciation | 101 |  |  | 95 |  |  | 301 |  |  | 292 |
Amortization of intangible assets | 48 |  |  | 49 |  |  | 144 |  |  | 145 |
Operating profit as a % of sales | 27.0 | % |  | 26.0 | % |  | 26.8 | % |  | 28.0 | %
Depreciation as a % of sales | 4.1 | % |  | 4.0 | % |  | 4.2 | % |  | 4.1 | %
Amortization as a % of sales | 1.9 | % |  | 2.1 | % |  | 2.0 | % |  | 2.0 | %

Sales Growth and Core Sales Growth

| % Change Three-Month Period Ended September 26, 2025 vs. Comparable 2024 Period |  | % Change Nine-Month Period Ended September 26, 2025 vs. Comparable 2024 Period
Total sales growth (GAAP) | 4.0 | % |  | 1.0 | %
Impact of: |  |  |
Divestitures | 0.5 | % |  | 0.5 | %
Currency exchange rates | (1.0) | % |  | — | %
Core sales growth (non-GAAP) | 3.5 | % |  | 1.5 | %

Price decreases in the segment of 1.5% and 1.0%, attributable to the impact of sales promotions and factors discussed below, negatively impacted the year-over-year change in sales during both the three and nine-month periods ended September 26, 2025, respectively, and are reflected as a component of core sales above.
Total segment sales increased 4.0% during the three-month period primarily as a result of increased core sales and to a lesser extent, currency exchange rates, net of the impact of divestitures. Total segment sales increased 1.0% during the nine-month period primarily as a result of increased core sales, net of the impact of divestitures. In the three and nine-month periods, the increase in segment core sales was primarily driven by increased year-over-year demand for consumables. Geographically, increased core sales in North America and most other major markets were partially offset by decreased core sales in China in both periods attributable to the pricing impact of China’s volume-based procurement program and healthcare reimbursement changes.
During the three-month period, core sales growth in the molecular diagnostics business increased year-over-year primarily due to increased core sales in respiratory tests. During the nine-month period, core sales increased year-over-year as increased core sales of non-respiratory tests more than offset decreased core sales of respiratory tests. The Company believes that third quarter 2025 demand for respiratory tests was driven in part by customers purchasing in preparation for the upcoming respiratory season, which may adversely impact demand for such tests in the fourth quarter of 2025. In the segment’s clinical diagnostics businesses core sales increased during both the three and nine-month periods on a year-over-year basis, led by the pathology diagnostics business. In the clinical lab business, increased year-over-year core sales outside of China, led by North America, more than offset core sales declines in China in both the three and nine-month periods, due to the impact of China’s volume-based procurement program and healthcare reimbursement changes.
Operating Profit Performance
Operating profit margin increased 100 basis points during the three-month period ended September 26, 2025 as compared to the comparable period of 2024.
Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were favorably impacted by:
•Higher third quarter 2025 core sales and improvements in leverage in the segment’s operational and administrative cost structure, net of the impact of product mix - 170 basis points
34

Table of Contents
Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were unfavorably impacted by:
•Third quarter 2025 impairment charge related to a trade name - 60 basis points
•Third quarter 2025 impact of a product line disposition which did not qualify as discontinued operations - 10 basis points
Operating profit margin decreased 120 basis points during the nine-month period ended September 26, 2025 as compared to the comparable period of 2024. The following factors unfavorably impacted year-over-year operating profit margin:
•The impact of product mix and currency exchange rates, net of higher 2025 core sales and improvements in leverage from the segment’s operational and administrative cost structure - 85 basis points
•First nine months of 2025 impairment charge related to a trade name - 20 basis points
•First nine months of 2025 impact of a product line disposition which did not qualify as discontinued operations - 15 basis points
COST OF SALES AND GROSS PROFIT

| Three-Month Period Ended |  | Nine-Month Period Ended
($ in millions) | September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Sales | $ | 6,053 |  |  | $ | 5,798 |  |  | $ | 17,730 |  |  | $ | 17,337 |
Cost of sales | (2,530) |  |  | (2,397) |  |  | (7,173) |  |  | (7,021) |
Gross profit | $ | 3,523 |  |  | $ | 3,401 |  |  | $ | 10,557 |  |  | $ | 10,316 |
Gross profit margin | 58.2 | % |  | 58.7 | % |  | 59.5 | % |  | 59.5 | %

Cost of sales increased year-over-year during both the three and nine-month periods ended September 26, 2025 as compared to the comparable periods in 2024. The increase during both periods was primarily due to the impact of higher year-over-year sales volumes, currency exchange rates and product mix. The increase during the nine-month period also reflected a $15 million impairment charge related to a facility in the Biotechnology segment. These increases were partially offset by a $25 million acquisition-related charge associated with the fair value adjustment to inventory recorded in the first nine months of 2024 in connection with the acquisition of Abcam plc.
Year-over-year gross profit margin decreased during the three-month period ended September 26, 2025 as compared to the comparable period in 2024 primarily due to product mix, the impact of currency exchange rates and tariff costs, partially offset by the impact of continued productivity improvement initiatives and higher year-over-year sales volumes. Year-over-year gross profit margin remained consistent in the nine-month period ended September 26, 2025 as compared to the comparable prior year period as higher year-over-year sales volumes and the impact of product mix were offset by the impact of currency exchange rates and tariff costs. Gross margin was also impacted by the acquisition-related charge recorded in the first nine months of 2024, net of the facility impairment recorded in the first nine months of 2025, both referenced above.
OPERATING EXPENSES

| Three-Month Period Ended |  | Nine-Month Period Ended
($ in millions) | September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Sales | $ | 6,053 |  |  | $ | 5,798 |  |  | $ | 17,730 |  |  | $ | 17,337 |
Selling, general and administrative expenses | 1,991 |  |  | 2,060 |  |  | 6,209 |  |  | 5,736 |
Research and development expenses | 378 |  |  | 383 |  |  | 1,160 |  |  | 1,142 |
SG&A as a % of sales | 32.9 | % |  | 35.5 | % |  | 35.0 | % |  | 33.1 | %
R&D as a % of sales | 6.2 | % |  | 6.6 | % |  | 6.5 | % |  | 6.6 | %

SG&A expenses as a percentage of sales decreased year-over-year during the three-month period ended September 26, 2025 and increased year-over-year during the nine-month period ended September 26, 2025 as compared to the comparable periods in 2024. The decrease during the three-month period was primarily due to the $222 million impairment charge recorded in the third quarter of 2024, partially offset by the $101 million of impairment charges incurred in the third quarter of 2025. To a lesser extent, the decrease was driven by incremental year-over-year cost savings associated with continuing productivity improvement initiatives and cost structure improvements, net of a year-over-year increase in costs incurred for productivity improvement actions. The increase in SG&A as a percentage of sales during the nine-month period ended September 26, 2025 was primarily driven by the $548 million of impairment charges recorded in the first nine months of 2025, partially offset by the $222 million impairment charge recorded in the third
35

Table of Contents
quarter of 2024. To a lesser extent, the increase was driven by a year-over-year increase in costs incurred for productivity improvement actions, net of incremental year-over-year cost savings associated with continuing productivity improvement initiatives and cost structure improvements. Refer to Note 8 to the accompanying Consolidated Condensed Financial Statements for additional information regarding the impairment charges.
R&D expenses (consisting principally of internal and contract engineering personnel costs) as a percentage of sales decreased during the three-month period ended September 26, 2025 and remained essentially flat during the nine-month period ended September 26, 2025 as compared to the comparable periods of 2024. The decrease in the three-month period was primarily a result of the timing of spending on new product research and the impact of higher year-over-year sales. In the nine-month period, increased R&D spending correlated to the increase in sales.
OTHER INCOME (EXPENSE), NET
For a description of the Company’s other income (expense), net during the three and nine-month periods ended September 26, 2025 and September 27, 2024, refer to Note 7 to the accompanying Consolidated Condensed Financial Statements.
INTEREST COSTS AND FINANCING
For a discussion of the Company’s outstanding indebtedness, refer to Note 10 to the accompanying Consolidated Condensed Financial Statements.
Interest expense of $67 million and $210 million for the three and nine-month periods ended September 26, 2025, respectively, was $20 million lower and $7 million lower than the comparable periods of 2024, due primarily to a lower average interest rate on the Company’s commercial paper borrowings versus the comparable periods of 2024, partially offset by the impact of currency exchange rates.
Interest income of $3 million and $17 million for the three and nine-month periods ended September 26, 2025, respectively, was $1 million lower and $86 million lower than the comparable periods of 2024, due primarily to lower average cash balances in 2025 as a result of share repurchases.
INCOME TAXES
The following table summarizes the Company’s effective tax rate:

| Three-Month Period Ended |  | Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024 |  | September 26, 2025 |  | September 27, 2024
Effective tax rate | 15.6 | % |  | 16.3 | % |  | 15.5 | % |  | 15.6 | %

The Company operates globally, including in certain jurisdictions with lower tax rates than the U.S. federal statutory rate. Therefore, the impact of Danaher’s global operations and benefits from tax credits and incentives contributes to a lower effective tax rate compared to the U.S. federal statutory tax rate. For each period presented, the effective tax rate differs from the U.S. federal statutory rate of 21.0% principally due to the impact of the Company’s global operations, research tax credits, foreign-derived intangible income and aggregate net discrete benefits or charges.
For the three-month period ended September 26, 2025, the effective tax rate was reduced by the tax effect from intangible asset impairments in jurisdictions with higher statutory tax rates than the Company’s effective tax rate, which reduced the effective tax rate by 1.3%. There was no net discrete tax charge in the three-month period, as a valuation allowance recorded on certain foreign operating losses was offset by benefits from the remeasurement of deferred taxes in a jurisdiction which enacted a tax rate change.
For the three-month period ended September 27, 2024, the effective tax rate included the tax effect from an intangible asset impairment in a jurisdiction with a higher statutory tax rate than the Company’s effective tax rate, which reduced the effective tax rate by 1.4%. There was no net discrete tax benefit in the three-month period, as excess tax benefits from stock-based compensation were offset by other discrete tax charges.
For the nine-month period ended September 26, 2025, the effective tax rate was reduced by the tax effect from intangible asset impairments in jurisdictions with higher statutory tax rates than the Company’s effective tax rate, the remeasurement of deferred taxes in a jurisdiction which enacted a tax rate change and the release of reserves for uncertain tax positions due to the expiration of statutes of limitations, partially offset by a valuation allowance recorded on certain foreign operating losses and changes in uncertain tax positions. The net impact reduced the effective tax rate by 1.2%.
For the nine-month period ended September 27, 2024, aggregate net discrete tax benefits reduced the effective tax rate by 1.4% and related primarily to excess tax benefits from stock-based compensation, release of reserves for uncertain tax positions due to the expiration of statutes of limitation and changes in estimates associated with prior period uncertain tax
36

Table of Contents
positions. The effective tax rate for this period also included the tax effect from an intangible asset impairment, which reduced the effective tax rate by 0.5%.
The Company (including its subsidiaries) conducts business globally, and files numerous consolidated and separate income tax returns in federal, state and foreign jurisdictions. In addition to the Company’s significant presence in the U.S., the Company also has a significant presence in China, Denmark, Germany, Singapore, Sweden, Switzerland and the United Kingdom. Excluding these jurisdictions, the Company believes that a change in the statutory tax rate of any individual foreign country would not have a material impact on the Company’s financial statements given the geographical dispersion of the Company’s taxable income.
The Company and its subsidiaries are routinely examined by various U.S. and non-U.S. taxing authorities. The IRS has completed substantially all of the examinations of the Company’s federal income tax returns through 2015 and is currently examining certain of the Company’s federal income tax returns for 2016 through 2022. In addition, the Company has subsidiaries in Canada, China, Denmark, France, Germany, India, Italy, Switzerland, the United Kingdom and various other countries, states and provinces that are currently under audit for years ranging from 2004 through 2023.
In the fourth quarter of 2022, the IRS proposed significant adjustments to the Company’s taxable income for the years 2016 through 2018 with respect to the deferral of tax on certain premium income related to the Company’s self-insurance programs. For income tax purposes, the recognition of premium income has been deferred in accordance with U.S. tax laws related to insurance. The proposed adjustments would have increased the Company’s taxable income over the 2016 through 2018 periods by approximately $2.5 billion. In the first quarter of 2023, the Company settled these proposed adjustments with the IRS, although the audit is still open with respect to other matters for the 2016 through 2018 period. The impact of the settlement with respect to the Company’s self-insurance policies was not material to the Company’s financial statements, including cash flows and the effective tax rate. As the settlement with the IRS was specific to the audit period, the settlement does not preclude the IRS from proposing similar adjustments to the Company’s self-insurance programs with respect to periods after 2018. Management believes the positions the Company has taken in its U.S. tax returns are in accordance with the relevant tax laws.
On July 4, 2025, the OBBBA was enacted, which includes permanent extensions of most expiring Tax Cuts and Jobs Act provisions as well as international tax changes. The application of the OBBBA to the Company did not have a material impact on its financial statements during the three-month period ended September 26, 2025.
The Company expects its effective tax rate for the remainder of 2025 to be approximately 17.0% based on its projected mix of earnings. The Company’s effective tax rate could vary as a result of many factors, including but not limited to the following:
•The expected rate for the remainder of 2025 includes the anticipated discrete income tax benefits from excess tax deductions related to the Company’s stock compensation programs, which are reflected as a reduction in tax expense, though the actual benefits (if any) will depend on the Company’s stock price and stock option exercise patterns.
•The actual mix of earnings by jurisdiction could fluctuate from the Company’s projection.
•The tax effects of other discrete items, including accruals related to tax contingencies, the resolution of worldwide tax matters, tax audit settlements, statute of limitations expirations and changes in tax regulations.
•Any additional future changes in tax law or the implementation of increases in tax rates, the impact of future regulations and any related additional tax planning efforts to address these changes.
As a result of the uncertainty in predicting these items, it is reasonably possible that the actual effective tax rate used for financial reporting purposes will change in future periods compared to the estimate above.
Refer to Note 6 to the accompanying Consolidated Condensed Financial Statements for discussion regarding the Company’s significant tax matters.
COMPREHENSIVE INCOME
Comprehensive income decreased by approximately $1.2 billion and increased by approximately $1.8 billion for the three and nine-month periods ended September 26, 2025, respectively, as compared to the comparable periods of 2024. For the three-month period ended September 26, 2025, the decrease in comprehensive income was primarily driven by decreased gains from foreign currency translation adjustments, partially offset by higher net earnings. For the nine-month period ended September 26, 2025, the increase in comprehensive income was primarily driven by increased gains from foreign currency translation adjustments and, to a lesser extent, gains on cash flow hedges, partially offset by lower net earnings. The Company recorded foreign currency translation losses of $71 million and gains of approximately $1.2 billion for the three-month periods ended September 26, 2025 and September 27, 2024, respectively. The Company
37

Table of Contents
recorded foreign currency translation gains of approximately $2.4 billion and $389 million for the nine-month periods ended September 26, 2025 and September 27, 2024, respectively. The foreign currency translation losses in the three-month period ended September 26, 2025 were primarily driven by the change in the exchange rates between the U.S. dollar, Swedish krona and the British pound, while the gains in the nine-month period ended September 26, 2025 were primarily driven by the change in the exchange rates between the U.S. dollar, Swedish krona, the British pound and the euro. Foreign currency translation adjustments reflect the gain or loss resulting from the impact of the change in currency exchange rates on the Company’s foreign operations as they are translated to the Company’s reporting currency, the U.S. dollar. The Company recorded gains of $48 million and $217 million from cash flow hedge adjustments related to the Company’s cross-currency swap derivative contracts for the three and nine-month periods ended September 26, 2025, respectively, as compared to gains of $63 million and of $43 million for the comparable periods of 2024.
LIQUIDITY AND CAPITAL RESOURCES
Management assesses the Company’s liquidity in terms of its ability to generate cash to fund its operating, investing and financing activities. The Company continues to generate substantial cash from operating activities and believes that its operating cash flow, cash on hand and other sources of liquidity will be sufficient to allow it to continue investing in existing businesses (including capital expenditures), consummating strategic acquisitions and investments, paying interest and servicing debt, paying dividends and funding restructuring activities, as well as to repurchase common stock when deemed appropriate and manage its capital structure on a short-term and long-term basis.
The Company has relied primarily on borrowings under its commercial paper program to address liquidity requirements that exceed the capacity provided by its operating cash flows and cash on hand, while also accessing the capital markets from time to time including to secure financing for more significant acquisitions or to take advantage of favorable interest rate environments or other market conditions. Subject to any limitations that may result from market disruptions, the Company anticipates following the same approach in the future.
Overview of Cash Flows and Liquidity
Following is an overview of the Company’s cash flows and liquidity ($ in millions):

| Nine-Month Period Ended
| September 26, 2025 |  | September 27, 2024
Net cash provided by operating activities | $ | 4,299 |  |  | $ | 4,669 |
Cash paid for acquisitions | $ | — |  |  | $ | (525) |
Payments for additions to property, plant and equipment | (785) |  |  | (876) |
Proceeds from sales of property, plant and equipment | 10 |  |  | 12 |
Payments for purchases of investments | (79) |  |  | (188) |
Proceeds from sales of investments | 12 |  |  | 251 |
Proceeds from sale of product line | 9 |  |  | — |
All other investing activities | 21 |  |  | 39 |
Total cash used in investing activities | $ | (812) |  |  | $ | (1,287) |
Proceeds from the issuance of common stock in connection with stock-based compensation, net | $ | 39 |  |  | $ | 143 |
Payment of dividends | (652) |  |  | (573) |
Net proceeds from borrowings (maturities of 90 days or less) | 22 |  |  | 1 |
Borrowings (maturities longer than 90 days) | 4 |  |  | — |
Repayments of borrowings (maturities longer than 90 days) | (500) |  |  | (974) |
Payments for repurchase of common stock | (3,088) |  |  | (5,170) |
All other financing activities | (108) |  |  | (120) |
Total cash used in financing activities | $ | (4,283) |  |  | $ | (6,693) |

As of September 26, 2025, the Company held approximately $1.5 billion of cash and cash equivalents.
38

Table of Contents
Operating Activities
Cash flows from operating activities can fluctuate significantly from period-to-period as working capital needs and the timing of payments for income taxes, restructuring activities and productivity improvement initiatives and other items impact reported cash flows.
Operating cash flows were approximately $4.3 billion for the first nine months of 2025, a decrease of $370 million, or 8%, as compared to the comparable period of 2024. The year-over-year change in operating cash flows from 2024 to 2025 was primarily attributable to the following factors:
•2025 operating cash flows reflected a decrease of $396 million in net earnings for the first nine months of 2025 as compared to the comparable period in 2024.
•Net earnings for the first nine months of 2025 also included $519 million higher year-over-year noncash charges primarily for impairments, as well as for unrealized investment gains/losses, intangible asset amortization, depreciation and stock compensation expense, net of a year-over-year decrease in amortization of an acquisition-related inventory step-up and a 2025 pretax gain on the sale of a product line. Depreciation expense relates to the Company’s manufacturing and operating facilities as well as instrumentation leased to customers under OTL arrangements. Depreciation, amortization, impairments and stock compensation are noncash expenses that decrease earnings without a corresponding impact to operating cash flows. Unrealized investment gains/losses impact net earnings without immediately impacting cash flows as the cash flow impact from investments occurs when the invested capital is returned to the Company.
•The aggregate of trade accounts receivable, inventories and trade accounts payable used $441 million in operating cash flows during the first nine months of 2025, compared to $179 million of operating cash flows provided in the comparable period of 2024. The amount of cash flow generated from or used by the aggregate of trade accounts receivable, inventories and trade accounts payable depends upon how effectively the Company manages the cash conversion cycle, which effectively represents the number of days that elapse from the day it pays for the purchase of raw materials and components to the collection of cash from its customers and can be significantly impacted by the timing of collections and payments in a period.
•The aggregate of prepaid expenses and other assets, deferred income taxes and accrued expenses and other liabilities used $424 million of operating cash flows during the first nine months of 2025, compared to $551 million of operating cash flows used in the comparable period of 2024. The timing of cash income tax payments and customer funding, net of normal operations drove the majority of this change.
Investing Activities
Cash flows relating to investing activities consist primarily of cash used for acquisitions and capital expenditures, including instruments leased to customers, cash used for investments and cash proceeds from divestitures of businesses or assets.
Net cash used in investing activities decreased $475 million in the nine-month period ended September 26, 2025 compared to the comparable period of 2024, primarily as a result of a decrease in cash paid for acquisitions, purchases of investments and capital expenditures, partially offset by lower proceeds from the sales of investments. In addition, during the nine-month periods ended September 26, 2025 and September 27, 2024 the Company invested $79 million and $188 million, respectively, in non-marketable equity securities and partnerships.
Though the relative significance of particular categories of capital investment can change from period to period, capital expenditures are typically made for the manufacture of instruments that are used in OTL arrangements that certain of the Company’s businesses enter into with customers, increasing manufacturing capacity, replacing equipment, purchasing facilities, supporting new product development and improving IT systems. Capital expenditures decreased $91 million on a year-over-year basis for the nine-month period ended September 26, 2025 compared to the comparable period in 2024.
Financing Activities and Indebtedness
Cash flows relating to financing activities can consist of cash flows associated with the issuance and repayments of commercial paper, issuance and repayment of long-term debt, borrowings under committed credit facilities, issuance and repurchases of common stock, issuance of preferred stock and payments of cash dividends to shareholders. Financing activities used cash of approximately $4.3 billion during the nine-month period ended September 26, 2025 compared to approximately $6.7 billion of cash used in the comparable period of 2024. The year-over-year decrease in cash used in financing activities was primarily due to lower repurchases of the Company’s common stock in the 2025 period compared to 2024 and lower repayments of long-term borrowings in 2025 compared to 2024, partially offset by lower proceeds from the issuance of common stock in connection with stock-based compensation and higher dividend payments year-over-year.
39

Table of Contents
On October 10, 2025, DH Switzerland Finance S.a.r.l., a wholly-owned finance subsidiary of the Company, completed an underwritten offering of Swiss franc-denominated bonds and received net proceeds from the issuance, after underwriting discounts and commissions and offering expenses, of approximately CHF 1.2 billion (approximately $1.6 billion based on currency exchange rates as of the date of the pricing of the Swiss Bonds). For a description of the Company’s outstanding debt as of September 26, 2025, long-term debt repayments, the Swiss Bond issuance and the Company’s commercial paper programs and credit facility, refer to Note 10 to the accompanying Consolidated Condensed Financial Statements. As of September 26, 2025, the Company was in compliance with all of its respective debt covenants.
Stock Repurchase Program
For information regarding the Company’s stock repurchase program and repurchases of common stock, refer to Part II—Item 2, “Unregistered Sales of Equity Securities and Use of Proceeds”.
Dividends
Aggregate cash payments for dividends on Company common stock during the nine-month period ended September 26, 2025 were $652 million compared to $573 million for the nine-month period ended September 27, 2024. The increase in dividend payments on the Company’s common stock compared to the comparable period of 2024 is due to the increases in the quarterly dividend rate for common stock beginning with respect to the dividends paid in the second quarters of each of 2024 and 2025, partially offset by lower average common stock outstanding.
In the third quarter of 2025, the Company declared a regular quarterly dividend of $0.32 per share of Company common stock payable on October 31, 2025 to holders of record as of September 26, 2025.
Cash and Cash Requirements
As of September 26, 2025, the Company held approximately $1.5 billion of cash and cash equivalents that were held on deposit with financial institutions or invested in highly liquid investment-grade debt instruments with a maturity of 90 days or less. Of the cash and cash equivalents, $207 million was held within the U.S. and approximately $1.3 billion was held outside of the U.S. The Company will continue to have cash requirements to support general corporate purposes, which may include working capital needs, capital expenditures, acquisitions and investments, paying interest and servicing debt, paying taxes and any related interest or penalties, funding its restructuring activities and pension plans as required, paying dividends to shareholders, repurchasing shares of the Company’s common stock and supporting other business needs.
The Company generally intends to use available cash and internally generated funds to meet these cash requirements, but in the event that additional liquidity is required, the Company may also borrow under its commercial paper programs (if available) or borrow under the Company’s Credit Facility, enter into new credit facilities and either borrow directly thereunder or use such credit facilities to backstop additional borrowing capacity under its commercial paper programs (if available) and/or access the capital markets (if available). The Company also may from time to time seek to access the capital markets to take advantage of favorable interest rate environments or other market conditions. With respect to the commercial paper and any other notes scheduled to mature during the next twelve months, the Company expects to repay the principal amounts when due using available cash, proceeds from new issuances of commercial paper (if available), drawing on its Credit Facility and/or proceeds from other debt issuances. Refer to Note 10 to the accompanying Consolidated Condensed Financial Statements for additional information regarding the classification of commercial paper and other notes scheduled to mature during the next twelve months.
While repatriation of some cash held outside the U.S. may be restricted by local laws, most of the Company’s foreign cash could be repatriated to the U.S. Following enactment of the Tax Cuts and Jobs Act and the associated Transition Tax, in general, repatriation of cash to the U.S. can be completed with no incremental U.S. tax; however, repatriation of cash could subject the Company to non-U.S. taxes on distributions. The cash that the Company’s non-U.S. subsidiaries hold for indefinite reinvestment is generally used to finance foreign operations and investments, including acquisitions. The income taxes, if any, that would be applicable to the repatriation of such earnings (including basis differences in our foreign subsidiaries) are not readily determinable. As of September 26, 2025, management believes that it has sufficient sources of liquidity to satisfy its cash needs, including its cash needs in the U.S.
CRITICAL ACCOUNTING ESTIMATES
The Company is supplementing the critical accounting estimates as described in the 2024 Annual Report with the following critical accounting estimate. There have been no other material changes to the Company’s critical accounting estimates as described in the 2024 Annual Report.
Acquired intangibles - The Company reviews identified intangible assets for impairment whenever events or changes in circumstances indicate that the related carrying amounts may not be recoverable. Determining whether an impairment loss occurred for finite-lived intangibles requires a comparison of the carrying amount of the asset group to the sum of undiscounted cash flows expected to be generated by the asset group. These analyses require management to make
40

Table of Contents
judgments and estimates about future revenues, expenses, market conditions and discount rates related to these assets. Indefinite-lived intangibles are subject to impairment testing at least annually or more frequently if events or changes in circumstances indicate that potential impairment exists. Determining whether an impairment loss occurred for indefinite-lived intangible assets involves calculating the fair value of the indefinite-lived intangible assets and comparing the fair value to their carrying value. In addition, the Company reviews the useful lives for intangible assets and whether events or changes in circumstances indicate that an indefinite life may no longer be appropriate. If the fair value is less than the carrying value, the difference is recorded as an impairment loss. If actual results are not consistent with management’s estimates and assumptions, goodwill and other intangible assets may be overstated, and a charge would need to be taken against net earnings which would adversely affect the Company’s financial statements.
The Company estimates the fair value of acquired trade names through the use of a relief from royalty method, which values an indefinite-lived intangible asset by estimating the royalties saved through the ownership of an asset. Under this method, an owner of an indefinite-lived intangible asset determines the arm’s length royalty that likely would have been charged if the owner had to license the asset from a third-party. The royalty rate, which is based on the estimated rate applied against forecasted sales, is tax-effected and discounted to present value using a discount rate commensurate with the relative risk of achieving the cash flow attributable to the asset. Management judgment is necessary to determine key assumptions, including revenue growth rates, perpetual revenue growth rates, royalty rates and discount rates. As further described in Note 8 to the accompanying Consolidated Condensed Financial Statements, in connection with the decision to reorganize and integrate certain genomics consumables businesses in the Life Sciences operating segment, the Company recorded a noncash impairment charge of $432 million pretax ($328 million after-tax) for the nine-month period ended September 26, 2025 related to a trade name. The charge is included in SG&A expenses in the accompanying Consolidated Condensed Statement of Earnings. Following this impact, if the fair value of the trade name declined by 10%, the Company estimates it would record an additional impairment charge of $8 million.
Goodwill is evaluated for impairment on a reporting unit basis. Reporting units resulting from recent acquisitions generally present the highest risk of impairment. Management believes the impairment risk associated with these reporting units generally decreases as these businesses are integrated into the Company and better positioned for potential future earnings growth. The Company’s reorganization and integration of certain businesses in the Life Sciences operating segment at the beginning of the third quarter of 2025, as described in the previous paragraph, changed two of its five goodwill reporting units and triggered a goodwill impairment analysis. The Company performed goodwill impairment analyses prior to, and after, the change in reporting units and in both instances, the fair values of the Company’s reporting units exceeded their carrying values and consequently did not result in an impairment charge. In the test of the prior reporting units, the excess of the estimated fair value over carrying value (expressed as a percentage of carrying value for the respective reporting unit) for each of the previous reporting units as of the testing date ranged from approximately 30% to approximately 365%. The excess of the estimated fair value over carrying value for each of the Company’s current reporting units as of the testing date ranged from approximately 40% to approximately 365%. The decrease in the excess of the estimated fair value over carrying value from the Company’s 2024 annual goodwill impairment test to the third quarter 2025 tests reflect the 2025 business performance and the current trading multiples for companies operating in businesses similar to the Company’s reporting units (used within the market approach to estimate fair value under the goodwill impairment test). To evaluate the sensitivity of the fair value calculations used in both goodwill impairment tests, the Company applied a hypothetical 10% decrease to the fair values of each of the reporting units and compared those hypothetical values to the reporting unit carrying values. Based on this hypothetical 10% decrease, the excess of the estimated fair value over carrying value for each of the Company’s current reporting units ranged from approximately 30% to approximately 315%.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Quantitative and qualitative disclosures about market risk appear in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Financial Instruments and Risk Management,” in the Company’s 2024 Annual Report.
ITEM 4. CONTROLS AND PROCEDURES
The Company’s management, with the participation of the Company’s President and Chief Executive Officer, and Executive Vice President and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, the Company’s President and Chief Executive Officer, and Executive Vice President and Chief Financial Officer, have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective.
There have been no changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the Company’s most recent completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
41

Table of Contents
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
For information regarding legal proceedings, refer to Note 12 in the accompanying Consolidated Condensed Financial Statements and to “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Legal Proceedings” in the Company’s 2024 Annual Report.
Consistent with SEC Regulation S-K Item 103, the Company has elected to disclose those environmental proceedings (if any) with a governmental entity as a party where the Company reasonably believes such proceeding would result in monetary sanctions, exclusive of interest and costs, of $1 million or more.
ITEM 1A. RISK FACTORS
The Company is supplementing the risk factors previously disclosed in the Company's 2024 Annual Report with the following risk factor. Additional information regarding risk factors can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Information Related to Forward-Looking Statements,” in Part I—Item 2 of this Report and in Part I—Item 1A of Danaher’s 2024 Annual Report.
Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition can have an adverse effect on our business and financial statements.
Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition, including laws and policies in areas such as trade, manufacturing, government purchasing, healthcare, intellectual property, regulatory enforcement and investment/development, can adversely affect our business and financial statements. The U.S. has announced and/or implemented significant new tariffs on imports from a wide range of countries, which has prompted retaliatory tariffs by a number of countries and a cycle of retaliatory tariffs by both the U.S. and other countries. Subsequently, actions have been taken by the U.S. and certain other countries to modify certain of these tariffs and/or delay their effective dates; the U.S. has entered into trade agreements with certain countries implementing new tariffs; and in August 2025 the U.S. Court of Appeals for the Federal Circuit ruled that certain of the U.S. tariffs that have been implemented are contrary to law (though such ruling has been appealed by the U.S. administration and the U.S. Supreme Court has agreed to hear the case). As of October 20, 2025, a number of new tariffs remain in effect, including significant tariffs and export restrictions between the U.S. and China. Collectively, these tariffs increase the cost to us of supplies and components we import, which in turn has required and will require us to implement surcharges and/or increase the price of certain of our products, among other countermeasures; can increase the cost to our customers of certain of our finished goods, which together with the surcharges and price increases noted above can adversely impact demand for our products and our competitive positioning; could adversely impact the availability to us of certain products in certain countries and disrupt our supply chains, with related impacts to our operations; and could exacerbate inflation, diminish investment and result in broader negative impacts, economic instability and capital markets dislocation that may adversely impact demand for our products. In addition, whenever we are unable to fully recover higher costs, or whenever there is a time delay between the increase in costs and our ability to recover these costs, our margins and profitability are adversely affected. The delayed tariffs may take effect, the U.S. Supreme Court may overrule all or part of the ruling by the U.S. Court of Appeals for the Federal Circuit, the U.S. may implement additional tariffs and other measures, further retaliatory tariffs and other retaliatory actions may follow and the risks and adverse effects noted above may increase. Please see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for further discussion of the impact of these tariffs. Though the risks identified above in certain cases have already adversely impacted parts of our business, the full impact of these tariffs and other actions on the Company and on our business partners remains highly uncertain and subject to rapid change.
In addition, certain governments have implemented policies to induce “re-shoring” of supply chains, reduce reliance on imported supplies and promote national production. For example, the Chinese government has issued a series of policies in the past several years to promote the development and use of local medical devices.
All of the risks identified in this risk factor can adversely affect our business and financial statements.
42

Table of Contents
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
For an overview of the Company’s share repurchase programs, refer to Note 13 in the accompanying Consolidated Condensed Financial Statements.
The following table presents a summary of share repurchases made during the quarter ended September 26, 2025 (all share repurchases were made under the 2024 Repurchase Program):

Period |  | Total Number of Shares Purchased |  | Average Price Paid Per Share(a) |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs |  | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs |
June 28, 2025 - July 25, 2025 |  | 1,007,000 |  |  | $ | 202.75 |  |  | 1,007,000 |  |  | 10,993,000 |  |
July 26, 2025 - August 22, 2025 |  | 8,868,511 |  |  | 200.68 |  |  | 8,868,511 |  |  | 2,124,489 |  |
August 23, 2025 - September 26, 2025 |  | 124,489 |  |  | 209.81 |  |  | 124,489 |  |  | 37,000,000 |  |
Total |  | 10,000,000 |  |  | $ | 201.00 |  |  | 10,000,000 |  |  | 37,000,000 |  | (b)

(a) Amounts exclude excise taxes and other transaction costs.
(b) Includes 35,000,000 shares under the 2025 Repurchase Program and 2,000,000 under the 2024 Repurchase Program, authorized by the Company’s Board of Directors on September 9, 2025 and July 22, 2024, respectively.
ITEM 5. OTHER INFORMATION
Director and Officer Trading Arrangements
None of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this report.
43

Table of Contents
ITEM 6. EXHIBITS
(a)Exhibits:

3.1 | Restated Certificate of Incorporation of Danaher Corporation (incorporated by reference from Exhibit 3.1 to Danaher Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 29, 2012) |
3.2 | Amended and Restated By-laws of Danaher Corporation (incorporated by reference from Exhibit 3.1 to Danaher Corporation’s Current Report on Form 8-K filed September 10, 2025) |
10.1 | Letter Agreement by and between Danaher Corporation and Matthew Gugino dated July 21, 2025 (incorporated by reference from Exhibit 10.1 to Danaher Corporation’s Current Report on Form 8-K filed July 24, 2025)* |
10.2 | Agreement Regarding Competition and Protection of Proprietary Interests by and between Danaher Corporation and Matthew Gugino dated July 21, 2025 (incorporated by reference from Exhibit 10.2 to Danaher Corporation’s Current Report on Form 8-K filed July 24, 2025)* |
22.1 | Subsidiary guarantors and issuers of guaranteed securities and affiliates whose securities collateralize securities of the Registrant |
31.1 | Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2 | Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, As Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32.1 | Certification of Chief Executive Officer, Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
32.2 | Certification of Chief Financial Officer, Pursuant to 18 U.S.C. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
101.SCH | Inline XBRL Taxonomy Extension Schema Document |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

| * | Indicates management contract or compensatory plan, contract or arrangement.

44

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  | DANAHER CORPORATION
Date: | October 20, 2025 | By: | /s/ Matthew R. McGrew
|  |  | Matthew R. McGrew
|  |  | Executive Vice President and Chief Financial Officer
Date: | October 20, 2025 | By: | /s/ Christopher M. Bouda
|  |  | Christopher M. Bouda
|  |  | Vice President and Chief Accounting Officer

45